Study Title: 
Sponsor: 
IND Number: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: 
[COMPANY_009] Study Clinical 
Program Manager: 
[COMPANY_009] Medical 
Monitor: 
Protocol Version/Date: (rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety 
and Efficacy of Switching from a Regimen of Dolutegravir and 
ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG /3TC 
to a FDC of GS-9883/F IT AF in HIV -[ADDRESS_122287] 
Foster City, CA [ZIP_CODE] 
125589 
2015-004025-14 
Not Available 
HIV -1 Infection 
GS-US-3 80-1844 
Name: [CONTACT_110109]: [COMPANY_003] 
Fax: [COMPANY_003] 
Name: 
[CONTACT_10880]: 
Fax: 
Mobile: 
Original: ...._ ____ _, 
Javier Szwarcbe rg, MD 
[COMPANY_003] 
[COMPANY_003] 
[COMPANY_003] 
21 October 2015 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, pmiicularly unpublished data, is the prope1iy or 
under control of [COMPANY_009] Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by [CONTACT_10825], your staff, and an applicable Institutional 
Review Bom·d or Independent Ethics Committee. The infonnation is only to be used by [CONTACT_110089] n with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the infonnation to others without written authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessmy to obtain infonned consent from those 
persons to whom the dmg may be administered. 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122288] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS.................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 16
1.1. Background ............................................................................................................................................ 16
1.2. GS-9883 ..............................................................................................................................
................... 17
1.2.1. General Information ............................................................................................................. 17
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 17
1.2.3. Clinical Trials of GS -9883 ................................................................................................... 19
1.3. Information about Emtricitabine (Emtriva®, FTC) ............................................................................... 27
1.4. Information about Tenofovir alafenamide (TAF, GS -7340) .................................................................. 27
1.4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) 
or Fixed Dose Combination emtricitabine/tenofovir alafenamide 
(FTC/TAF) ........................................................................................................................... 28
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) ........................... 29
1.5. Information about GS -9883/emtricitabine/tenofovir alafenamide (GS -9883/F/TAF) ........................... 31
1.5.1. GS-US-141-1233: Relative Bioavailability of GS -9883, FTC, and TAF 
betw een GS -9883/F/TAF and GS -9883 + F/TAF................................................................ 31
1.6. Information about abacavir/dolutegravi r/lamivudine (ABC/DTG/3TC Triumeq®)............................... 32
1.7. Rationale for this Study .......................................................................................................................... 32
1.8. Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_122289] Selection ............................................................................................ 40
4.2. Inclusion Criteria ..............................................................................................................................
......40
4.3. Exclusion Criteria ................................................................................................................................... 41
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 43
5.1. Randomization, Blinding an d Treatm ent Codes .................................................................................... 43
5.1.1. Procedures for Breaking Treatment Codes ........................................................................... 43
5.2. Description and Handling ....................................................................................................................... 44
5.2.1. Form ulation .......................................................................................................................... 44
5.2.2. Packaging and Labeling ....................................................................................................... 44
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 3 21October [ZIP_CODE].2.3. Storage and Handling ........................................................................................................... 45
5.3. Dosage and Administration of GS -9883/Em tricitabine/Tenofovir alafenamide and 
Abacavir/Dolu tegravir/Lamivudine ....................................................................................................... [ADDRESS_122290] (IMP) ................................................................. [ADDRESS_122291] Enrollment and Treatment Assignment ..................................................................................... 48
6.2. Pretreatment Assessments ...................................................................................................................... 48
6.2.1. Screening Visit ..................................................................................................................... 48
6.2.2. Day 1 Assessments ............................................................................................................... 50
6.3. Randomization ....................................................................................................................................... 51
6.4. Treatment Assessments (Week 4 -48)................................................................................................... 52
6.5. Treatment Assessments (Post Week 48 until the Unblinding Visit) ...................................................... [ADDRESS_122292] Study Care ...................................................................................................................................... 62
6.13. Virologic Failure .................................................................................................................................... 62
6.13.1. Management of Virologic Rebound ..................................................................................... 62
6.13.2. Subjects with HIV -1 RNA ≥50copi[INVESTIGATOR_014]/mL at Study Drug 
Discontinuation, or Week 48 ................................................................................................ 64
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ............................................................................... 65
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 65
7.1.1. Adverse Events ..................................................................................................................... 65
7.1.2. Serious Adverse E vents ........................................................................................................ 65
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 66
7.2. Assessment of Adverse Events and Serious Adverse Events .................................................................
66
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 66
7.2.2. Assessment of Severity ........................................................................................................ 67
7.3. Investigator Requirements and Instructions for 
Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 67
7.3.1. Adverse Events ..................................................................................................................... 67
7.3.2. Serious Adverse Events ........................................................................................................ 68
7.4. [COMPANY_009] Reporting Requirements ............................................................................................................. 69
7.5. Toxicity Management ............................................................................................................................ 69
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 69
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ............................................................. 70
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 70
7.5.4. Management of Possible Abacavir Hypersensitivity Reaction ............................................. 70
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 4 21October [ZIP_CODE].5.5. On-Treatment Hepatitis C Management ............................................................................... 71
7.6. Special Situations Reports ...................................................................................................................... 71
7.6.1. Definitions of Special Situations .......................................................................................... 71
7.6.2. Instructions for Reporting Special Situations ....................................................................... 72
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 74
8.1. Analysis Objectives and Endpoints ........................................................................................................ 74
8.1.1. Analysis Objectives .............................................................................................................. 74
8.1.2. Primary Endpoint ................................................................................................................. 74
8.1.3. Secondary Endpoint ............................................................................................................. 74
8.2. Analysis Conventions ............................................................................................................................. 74
8.2.1. Analysis Sets ........................................................................................................................ 74
8.3. Data Handling Conventions ................................................................................................................... 76
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 76
8.5. Efficacy Analysis ................................................................................................................................... 77
8.5.1. Primary Analysis .................................................................................................................. 77
8.5.2. Second ary Analyses ............................................................................................................. 78
8.6. Safety Analysis ...............................................................
........................................................................ 79
8.6.1. Extent of Exposure ............................................................................................................... 79
8.6.2. Adverse Events ..................................................................................................................... 79
8.6.3. Laboratory Evaluations ........................................................................................................ 80
8.6.4. Bone Safety Evaluations ...............................................................
....................................... 80
8.6.5. Other Safety Evaluations ...................................................................................................... 80
8.7. Pharm acokinetic Analysis ................................................................
...................................................... 80
8.8. Biomarker Anal ysis................................................................................................................................ 81
8.9. Patient Reported Outcomes (PRO) ......................................................................................................... [ADDRESS_122293] (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... [ADDRESS_122294] Accountability and Return ............................................. 85
9.1.8. Inspections ............................................................................................................................ 85
9.1.9. Protocol Compliance ...............................................................
............................................. 85
9.2. Sponsor Responsibilities ........................................................................................................................ 86
9.2.1. Protocol Modifications ......................................................................................................... 86
9.2.2. Study Report and Publications ............................................................................................. 86
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 86
9.3.1. Payment Reporting ............................................................................................................... 86
9.3.2. Access to Information for Monitoring .................................................................................. 87
9.3.3. Access to Information for Auditing or Inspections .............................................................. 87
9.3.4. Study Discontinuation .......................................................................................................... 87
10. REFERENCES ................................................................................................................................................... 88
11. APPENDICES .................................................................................................................................................... 89
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 5 21October 2015Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 90
Appendix 2. Study Procedures Table (Blinded Phase) ............................................................................... 91
Appendix 3. Management of Clinical and Laboratory Adverse Events ...................................................... 95
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 96
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) ........................... [ADDRESS_122295] OF IN -TEXT TABLES
Table 1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Follow ing Single Doses 
of GS -9883 in Healthy Subjects (GS -9883 PK Analysis Set; Part A: Single Dosing) ........... 21
Table 1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by [CONTACT_10827] -9883 Dose 
Follow ing Multiple -Dose Administration of GS -9883 (Analysis Set: GS -9883 PK 
Part B: Multiple
-Dose) ........................................................................................................... 22
Table 1-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic Parameters 
Follow ing Single -Dose Adm inistration of GS -9883 in the Fasted and Fed States 
(GS-
9883 PK Analysis Set) .................................................................................................... 23
Table 1
-4
. Trough GS -9883 Plasma Concentrations at Steady State Follow ing GS -9883 
Administration Under Fasting Conditions and Corresponding Protein -Adjusted 
IQ95 Values (GS-9883 PK Analysis Set) ............................................................................... 24
Table 1
-5. GS-US-141-1219: Trough GS -[ADDRESS_122296] OF IN -TEXT FIGURES
Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV -1 RNA 
(log 10copi[INVESTIGATOR_014]/mL) (PP Analysis Set) ...............................................................
........................ 24
Figure 3-1. Study Schema ......................................................................................................................... 38
Figure 6-1. Virologic Rebound Schema ...............................................................
..................................... 63
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122297]
Foster City, CA [ZIP_CODE]
StudyTitle: A Phase 3, Randomized, Double- Blind Study  to Evaluate the Safety  
and Efficacy  of Switching from a Regimen of Dolutegravir and 
ABC/3TC , or a Fixed Dose Combination (FDC) of ABC/DTG/3TC
to a FDC of GS -9883/ F/TAF in HIV -1 Infected Subjects who are 
Virologically  Suppressed
IND Numb er:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_2519]-004025-14
Not Available
Study Centers Planned: Approximately  75 centers in North America
Approximately  4centers in Asia Pacific
Approximately  26centers in Europe
Objectives: The primary  objective of this study  is:
To evaluate the efficacy of switching from a regimen of DTG 
and ABC/3TC or a fixed dose combination (F DC)of 
ABC/DTG/3TC toa FDC of GS -9883/F/TAF versus continuing 
DTG and ABC/3TC as the FDC ABC/DTG/3TC in 
virologicall y suppressed HIV-1 infected subjects as determined 
by [CONTACT_110090] (HIV -1 RNA 
≥
50copi[INVESTIGATOR_014]/mL ) at Week 48
The secondary  objectives of this study  are:
To evaluate the safet y and tolerability  of the 
two treatme nt 
groups through Week 48
To evaluate the bone safety  of the 
two treatment group sas 
determined b y the percentage change from baseline in hip and 
spi[INVESTIGATOR_1928]  (BMD) through Week 48
Study Design: Randomized, double -blind, multicenter, active -controlled study  to 
evaluate the safety and efficacy of switching to a FDC of 
GS-9883/ F/TAF tablet versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC i n HIV -1 infected subjects who are 
virologicall y suppr essed (HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on a stable 
regime n of DTG + ABC/3TC or ABC/DTG/3TC FDC for 
3months prior to screening.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 7 21October 2015Subjects who provide written consent and meet all eligibility  criteria 
will be randomized in a 1:1 ratio to one of the following 2 treatment 
group s:
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 
200mg/ tenofovir alaf enamide 25 mg (GS -9883/F/TAF) +Placebo 
to match FDC of abacavir 600 mg/ dolutegravir 50 mg/lamivudine 
300mg (ABC/DTG/3TC) administered orally , once dail y, without 
regard to food (n=260)
Treatment Group 2: FDC of abac avir 600 mg/dolutegravir 
50mg/lamivudine 300 mg (ABC/DTG/3TC) + Placebo to match 
FDC of GS -9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS -9883/F /TAF) administere d orall y, 
once daily, without regard to food (n=260)
Number of Subjects 
Planned:Appro ximately  520 subjects in total.
260 subjects in each Treatment Group 1 and Treatment Group 2
Target Population: HIV-1 infected adult subjects who are virologically  suppressed 
(HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL ) on a stable regimen of
DTG +ABC/3TC or ABC/DTG/3TC FDC for 3months prior to 
screening.
Duration of 
Treatment:Subjects will be treated for at least 48 weeks. Subjects’ treatme nts 
will be unblinded after the last subject completes the Week [ADDRESS_122298] been unblinded. At the Unblinding 
Visit, subjects in a country where GS -9883/F/TAF FDC is not 
available will be given the option to receive GS -9883/F/TAF FDC 
in an open label extension phase for [ADDRESS_122299].
After Week 48 Visit, subjects in the [LOCATION_008] 
([LOCATION_006]) and 
Sweden (SWE) will stop taki ng stud y drug and complete a [ADDRESS_122300] of care .
Subjects who complete the study  through the Unblinding Visit and 
do not continue on the open -label GS -9883/F/TAF FDC extension 
phase , will be requ ired to return to the clinic 30 days after 
unblinding visit for a 30 -Day Follow -Up Visit .
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 8 21October 2015Diagnosis and Main 
Eligibility  Criteria:Medically  stable HIV-1 infected subjects who meet the following 
criteria :
Currently  receiving an antiretroviral regimen of 
DTG +ABC/3TC, or ABC/DTG/3TC FDC for 3months prior 
to screening
Currently  on the first or second antiretroviral regimen, with 
documented plasma HIV 1 RNA < 50 copi[INVESTIGATOR_014]/mL on a stable 
regimen (or undetectable HIV
-1 RNA level according to the 
local assay  being used if the limit of detection is 
≥ 50 copi[INVESTIGATOR_014]/mL ) for ≥ 3 months preceding the Screening visit.
Prior changes in antiretroviral regimen are onl y allowed due 
to tolerability  issues or for regimen simplification. 
Unconfirmed virologic elevation sof ≥ 50 copi[INVESTIGATOR_014]/mL  
(transient detectable viremia, or “blip”) prior to screening are 
acceptable . If the lower limi t of detection of the local HIV -1 
RNA assay  is <50 copi[INVESTIGATOR_014]/mL  (eg, <20 copi[INVESTIGATOR_014]/mL), the 
plasma H IV-1 RNA level cannot exceed 50 copi[INVESTIGATOR_014]/mL  on 
twoconsecutive HIV -1 RNA tests .
Estimated GFR 50mL/min according to the Cockcroft- Gault 
formula for creatinine clearance
No chronic Hepatitis B Virus (HBV) infection, as determined b y 
either
Positive HBV surface antigen and negative HBV surface 
antibody , regardless of HBV core antibody  status, at the 
screening visit
Positive HBV core antibody  andnegative HBV surface 
antibody , regardless of HBV surface antigen status, at the 
screening visit
Study  Procedures/
Frequency :After screening procedures, eligible subjects will be randomized 1:[ADDRESS_122301] been unblinded (except the [LOCATION_006] and 
SWE).
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 9 21October 2015For all eligible subjects, blood w ill be collected at Day  1, Weeks 4, 
8, 12, and the n every  12 weeks through the unblinding visit .
Laboratory  anal yses (hematology , chemistry , and urinaly sis), HIV -1 
RNA, CD4+ cell count, and complete or s ymptom -directed ph ysical 
examinations will be performed at the Screening, Day 1 and all 
subsequent study  visits.
In addition, blood will be collected and stored for possible 
evaluation of markers of inflammation and immune activation, 
which may  include but not limited to: cy statin C, IL -6, hs-C RP, 
d-dimer, sCD14, and sCD163. Platelet function evaluations may  
also be assessed, including but not limited to soluble gl ycoprotein 
VI (sGPVI), P -selectin, an d soluble CD40 ligand . Urine will be 
collected for evaluations of renal tubular function including urine 
albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2microglobulin.
For all subjects on study  drug , except subjects located in 
German y, 
dual energy  x-ray absorptiometry  (DXA) scans will be performed 
prior to or within 24 hours of the Day 1 Visit , and then at 
Weeks 24, 48 and at the Unblinding Visit or Early  Study  Drug 
Discontinuation Visit, if > [ADDRESS_122302], Dose, and 
Mode of 
Administration:FDC of GS -9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS -9883/F /TAF) administered orall y, 
once daily without regard to food.
Reference Therapy, 
Dose, and Mode of 
Administration:FDC of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg 
(ABC/DTG/3TC) administered orall y, once dail y without regard to 
food.
Criteria for Evaluation:
Safety : Adverse events, clinical laboratory  tests and DXA
Efficacy : The primary  efficacy  endpoint is:
The proportion of subjects with virologic failure ( HIV-1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL )at Week 48 as defined b y the modified United 
States (US) Food and Drug Administration (FDA) snapshot 
algorithm
GS-9883/F/T AF 
Protocol GS-US-380-1844 
[COMPANY_009] Sciences, Inc. 
Phrumacokinetics: 
Optional Genomic 
Testing: 
CONFIDENTIAL The secondruy endpoints include: Final 
Original 
• The prop01iion of subjects with HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL at 
Week 48 as defmed by [CONTACT_10830] 
• The chan ge from baseline in CD4+ cell count at Week 48 
An intensive phannacokinetic (PK) substudy will be perf01med at 
the Weeks 4 or 8 visits in a subset of subjects (target n=30) at study 
sites able to conduct this testing. 
For all subjects on study dmg a single anytime pre or post-dose PK 
blood sample will be collected at Weeks 8, [ADDRESS_122303]-dose. 
For intensive PK substudy, the following PK parruneters for 
GS-9883 may be explored as applicable: 
Cmax, Tmax, Clast, Tiast, Ctau,Tll2, AUCtau,AUCo-Iast, VzJF, CLss/F 
The concentration of GS-9883 may be summarized using descriptive 
statistics. The phrumacokinetics of GS-9883 may be evaluated using 
population approaches. T AF and FTC concentrations may be 
analyzed and PK pru·ameters may be summarized as applicable. 
[COMPANY_003] 
Page 10 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 11 21October 2015Patient Reported 
Outcome:Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress 
Module, Wor k Productivity  and Activity  Impairment Questionnaire 
(WPA I) and Pi[INVESTIGATOR_110070] y Index (PSQI) will be 
administered at Day  1, Weeks 4, 12 and 48.
Statistical Methods: The primary  anal ysis will consist of a non- inferiority  
testof 
switching to FDC GS-9883/ F/TAF versus continuing DTG and 
ABC/3TC as the FDC of ABC/ DTG/ 3TC, with respect to the 
proportion of subjects with virologic failure ( HIV
-1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL )at Week 48as defined b y the modified US FDA 
snapshot algorithm . It will be concluded that GS -9883/ F/TAF is 
non-inferior to the ABC/3T C/DTG if the upper bound of the 2-sided 
95% confidence interval (CI) of the difference between treatment 
groups (GS -9883/F/TAF –ABC/3TC/DTG) in the virologic failure 
rate is less than 4% ;ie,a margin of 4% is applied to non -inferiorit y 
assessment. The 2-sided 95% CI s will be constructed based on the 
exact method.
The proporti on of subjects with HI V-1 RNA < 50copi[INVESTIGATOR_014]/mL  at 
Week 48 as defined by  [CONTACT_110091]. The 95% CIs will be constructed in the same manner 
as described for the primary  efficacy  endpoint.
The change from baseline in CD4+ cell count at Weeks 48 will be 
summarized by  [CONTACT_53846]. The 
differences and the associated 95% CIs will be constructed using an 
Analy sis of Variance (ANOVA) model, including treatment 
(GS-9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
The percent agechange from baseline in hip and spi[INVESTIGATOR_110071] 48 will be 
summarized by  [CONTACT_110092]. The differences and the associated 95% CI s will be 
conducted using an ANOVA model, including treatment group as a 
fixed effect in the model .
Adverse events, clinical laboratory assessment,
and pharmacokinetic 
parameters will be summarized using descriptive statistics.
A total of approximately  520 HIV-1 infected subjects, randomized 
in a 1:1 ratio to 2 treatment group s (260subjects per treatment 
group ), achieves at least 90% power to detect a non -inferiorit y 
margin of 
4%in Week 48 virologic failure rate (HIV -1 RNA
≥ 50 copie s/mL ) difference between the 2 treatment group s.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122304] a virologic failure rate of 2% (based on the 
historical [COMPANY_009] E/C/F/TAF and STB studies) , that a non -inferiorit y 
margin is 4%, and that the significanc e level of the test is at a 
one-sided 0.025 level
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 13 21October 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ABC/3TC abacavir/lamivudine, EpzicomKivexa
ABC/DTG/3TC abacavir/dolutegravir/lamivudine, Triumeq
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ARV antiretroviral
AST aspartate aminotransferase
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration 
versus time curve
BID twice a day 
BUN blood urea nitrogen
CBC complete blood count
CI confidence interval
CL cr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH Cochran -Mantel -Haenszel
CNS central nervous system
COBI, /co cobicistat (GS -9350)
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CYP cytochrome P450
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
DTG dolutegravir , Tivicay
ECG electrocardiogram
eCRF electronic case report form(s)
eGFR estimated glomerular filtration rate
EVG elvitegravir
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF elvitegravir/cobicistat/emtricitabine /tenofovir disoproxil fumarate, Stribild
FAS full analysis set
FDA ([LOCATION_002]) Food and Drug Administration
FDC fFixed dose combination
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 14 21October 2015FTC/TAF emtricitabine/tenofovir alafenamide 
FSH follicle -stimulating hormone
FTC, F emtricitabine, Emtriva
GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GLSM geometric least squares mean
GSI [COMPANY_009] Sciences, Inc.
GS-9883/F/TAF GS-9883/em tricitabine/tenofovir alafenamide
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDPE high-density polyethylene
hERG human Ether -à-go-go-Related Gene
HIV Human Immunodeficiency Virus
HIV Sx HIV Symptoms  Distress Module
HLA human leukocyte antigen
IB investigator’s brochure
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IND Investigational New Drug (Application)
INSTI integrase strand -transfer inhibitors
IRB institutional review board
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
MH Mantel- Haenszel
min minute
mmHg millimeters mercury
NNRTI non-nucleoside reverse transcriptase inhibitor
NOAEL no observed adverse effect level
NRTI nucleoside/nucleotide reverse transcriptase inhibitor
P-gp P-glycoprotein
PI [INVESTIGATOR_110072]-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 15 21October 2015PSQI Pi[INVESTIGATOR_110073] -to-match
QD once daily 
RAL raltegravir
RNA ribonucleic acid
SA single agent
SAE serious adverse even tt
SF-36 Short Form 36 Health Survey
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide 
TDF tenofovir disoproxil fumarate, Viread
TFV -DP tenofovir diphosphate (TFVpp)
tmax the time (observed time point) of C max
TSH thyroid stimulating hormone
UGT1A1 uridine 5' -diphospho -glucuronosyltransferase 
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
[LOCATION_006] [LOCATION_008]
US [LOCATION_002]
WPAI Work Productivity and Activity Impairment Questionnaire
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 16 21October [ZIP_CODE]. INTRODUCTION
1.1. Background
Human immunodeficiency virus -1 (HIV -1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.4million people in 
North America and Western and Central Europe living with HIV -1 and 36 million people 
worldwide {[ZIP_CODE]} . The infection, if left untreated or suboptimally  treated, is characterized b y 
deterioration in immune function, ultimately  resulting in death. Therapeutic strategies for the 
treatment of HIV -[ADDRESS_122305] been significantly  advanced by  [CONTACT_110093] y active 
antiretroviral therap y (HAART); the introducti on of HAART was associated with a dramatic 
decrease in acquired immune deficiency  syndrome (AIDS) -related morbidity  and mortalit y 
{[ZIP_CODE]} , {5125} , {8284} .
The success of potent and well- tolerated ART means that m orbidity  and mortality  in the 
HIV-infected population is increasingly  driven by  [CONTACT_105]- AIDS–
associated comorbidities. C linical 
attention has become more focused on the optimization of tolerability , long -term safety , and 
adherence of potent ART regimens { [ZIP_CODE]} . In addition, t here remains a significant medical need 
for new ,effective therapi[INVESTIGATOR_110074] , 
the aging 
HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen simplification.
For ART -naive HIV -infected patients, current treatment guidelines suggest that initial therapy  
consist of 2 nucleos(t)ide reverse transcr iptase inhibitors (N[t] RTI) and either 
an integrase 
strand- transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {[ZIP_CODE]} . 
Virologically  suppressed, HIV-infected patients may  switch from their current regimen because 
of safet y or tolerability concerns or for regimen simplification . All patient populations may  
benefit from once -daily  fixed -dose combination (FDC) regimens as these have been shown to 
provide increased adherence and improved clinical and virologic outcomes {[ZIP_CODE]
},{[ZIP_CODE] }
Tenofovir (TFV) is a nucleotide analog th at inhibits HI V-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, i s apreferred NtRTI for initial therapy , 
nephrotoxicity  is an identified risk, and reduc tions in bone mineral densit y (BMD) have been 
shown that are larger than those seen with other NRTI s
. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF ,provides higher intracellular 
levels of the active phosphory lated metabolite tenofovir diphosphate (TFV -DP),and
approximately  90% lower circulating levels of TFV relative to TDF
at the clinical doses. 
Thedistinct metaboli sm of TAF offers the potential for an improved clinical profile compared 
with TDF .
GS-[ADDRESS_122306] a panel of mutant 
viruses with resistance to NRTI s, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 
protease inhibitors (PIs).  I ntegrase mutant viruses that are resistant to the INSTI s raltegravir 
(RAL) and elvitegravir (EVG) remain largel y sensitive to GS -9883.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 17 21October 2015[COMPANY_009] Sciences ([COMPANY_009]) hascoformulated GS-9883 with the N RTI emtricitabine (FTC; F ) and 
the NtRTI  tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once -daily use . 
This GS- 9883/F/TAF FDC may  provide a potent, convenient, tolerable, and practical regimen 
for the l ong-term treatment of patients with HIV infection.
1.2. GS-[ADDRESS_122307] been conducted with GS -9883. These 
include assessments of cytotoxicity , off-target receptor and ion -channel binding, effects on 
human Ether -à-go-go-
Related Gene (hER G) potassium current and papi[INVESTIGATOR_10789], and in vivo studies in rats and dogs that evaluated effects of GS -9883 on all major 
organ s ystems. The volume of distribution of GS -9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical specie s, which indicates that the distribution of GS -9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half -life of GS -9883 in 
humans is approximately  20 hours based upon the estimates of clearance and vol ume of 
distribution .
[IP_ADDRESS]. Pharmacology
GS-[ADDRESS_122308] HIV replication in MT4 cells with an EC 50(50% 
effective inhibitory  concentration) value of 1.[ADDRESS_122309] dividing and non- dividing human 
PBMCs, primary  human hepatocy tes and various non- target human cell lines.
GS-9883 is mainly  metabolized by  [CONTACT_10834] 5' -diphospho -glucuronos yltransferase (UGT1A1) and 
CYP3A. GS-
9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25M. Consequently , GS-9883 is unlikely  to be a clinicall y relev ant inhibitor of these
enzy mes, and is not expected to inhibit the metabolic clearance of drugs metabolized by  [CONTACT_110094]. GS -9883 onl y modestly  inhibits renal transporter OCT2 (I C50= 0.42 M). As a result, 
GS-[ADDRESS_122310] the OCT2 -mediated excretion of co -administered drugs is considered to be low.
GS-9883 does not a ctivate AhR and onl y weakly activates PXR at concentrations up to 50 M 
(less than 5% and 40% of activation, respectivel y, compared to positive control compound). 
Therefore, GS -[ADDRESS_122311] sat the doses and exposure lev els projected in clinical use.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 18 21October [ZIP_CODE].2.2.2. Toxicology
Single oral doses of GS -9883 up to 1000 mg/kg were well -tolerated in rats (AD -141- 2286). The 
increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC 0-242205 gh/mL and 1931 gh/mL, respectively ). In monkey s, single oral doses of 
GS-9883 up to 1000 mg/kg were well- tolerated (AD -141- 2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC 0-[ZIP_CODE]gh/mL  and 1078 gh/mL , 
respectivel y).
In 2-week (TX -
141-2029) and 26- week (TX -141-2031) oral toxicity  studies in rats at doses up to 
300 mg/kg/day , GS-9883 was well- tolerated with no GS -9883-related effects on clinical 
observations, bod y weight, food consumption, ophthalmic examinations, and anatomic 
pathology .  The high dose of 300 mg/kg/day  was considered the maximum feasible dose based 
upon saturation of absorption. The no observed ef fect level (NOEL) in the 26- week stud y was 
considered to be the high dose of 300 mg/kg/day.  At the NOEL, GS -9883 exposures in the rat 
were considered to be approximately  12
-/31-fold higher (males/females) than the projected 
steady  state human exposure of GS -9883 following administration of GS -9883/F/TAF 
(50/200/25 mg)QD under fed conditions.
In a 39 -week study  in monkey s (TX -141- 2032), f ollowing administration of 1000 mg/kg/day  
(high dose) of GS -[ADDRESS_122312] 
hyperplasia and minimal or moderate hepatocy te hy pertrophy  in both sexes, and minimal 
regenerative h yperplasia and minimal or slight neutrophil infiltrate in males.  The macroscopic 
finding of rough surface on the live r in one male adminis
tered 1000 mg/kg/day  correlated with 
moderate hepatocy te hypertroph y and marked bile duct hyperplasia . After a [ADDRESS_122313] hy perplasia in one female administered 1000 mg/kg/day , while the 
other two animals in the high dose group had no hepatobiliary  findings . Minimally  to mildly  
increas ed ALT activities (≤ 3.5- fold versus baseline values) , 
likely associated with liver findings, 
exhibited reversibility . There were no other adverse findings in the study , including clinical 
observations ,or effects on body  weight, bod y weight change, food c onsumption, ECGs, 
hematology , coagulation, clinical chemistry , u
rinaly sis, and ophthalmoscopy .
No GS -9883- related effects were observed in the mid- dose group (200 mg/kg/day ) which was 
considered the no
-observed- effect -level ( NOEL ).  The estimated margin of exposure at the 
NOEL was approximately  4.7-fold based on expected human exposure with the once dail y 
dosing of the GS -9883/F/TAF (50/200/25 mg) tablet.
A standard battery  of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity  in an in vitro bacterial 
reverse mutation assay  (Study  TX-
141-2026), a chromosomal aberration assay  in human 
lymphocy tes (Study  TX-141- 2027), or in a rat micronucleus test (Stud y TX -141-2029).
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 19 21October [ZIP_CODE].2.3. Clinical Trials of GS-9883
Clinical trials entailing the use of GS- 9883 include:
GS-US-141- 1218, a Phase [ADDRESS_122314] -in-human, 
single -and multiple -ascending dose stud y evaluating the safet y, tolerability, and PK of oral 
GS-9883 in healthy  subjects and a randomized, open
-label, 2 -cohort, 3- period, crossover, PK 
study  evaluating the drug interaction potential between F/TAF FDC tablet and GS- 9883 in 
healthy  subjects (completed)
GS-US-141- 1219, a Phase 1b randomiz ed, double -blinded, sequential cohort
placebo
-controlled study  of the safet y, PK, and antiv iral activity  of GS -9883 in HIV -1 
infected subjects study  of the pharmacokinetics and antiviral activity  of GS -7340 
(8mg,25mg, 40mg) in HIV infected subjects (co mpleted)
GS-US-141-
1233, a Phase 1,Open -label, Two-Cohort, Multiple -Period, Fixed- Sequence,
Crossover Study  to Evaluate 1) the Relative Bioavailability  of
Two GS-9883/ Emtr
icit
abine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg)
Fixed -Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a Emtricitabine/Tenofovir 
Alafenamide (200/25 mg) Fixed -Dose Combination Tablet Adm inistered Simultaneously  and 
2) the Effect of Food on the Pharmacokinetics of GS- 9883, Emtricitabine and Tenofo vir 
Alafenamide When Administered as GS -9883/Emtricitabine/Tenofovir Alafenamide 
(75/200/25 mg and 50/200/25 mg) Fixed- DoseCombin ation Tablets (ongoing)
GS-US-141- 1479, a Phase 1, open- label, parallel -group, adaptive single -dose study  to 
evaluate the PK o f GS-
9883 in subjects with normal and impaired renal function (completed)
GS-US-141- 1480, a Phase [ADDRESS_122315] of GS
-9883 on the QT/QTc interval in healthy  subjects 
(complete d)
GS-US-141- 1481, a Phase 1 study  to evaluate the pharmacokinetics, metabolism, and 
excretion of GS -9883 in healthy  subjects (completed)
GS-US-141- 1485, a Phase 1 adaptive stud y to evaluate transporter, CYP -mediated and 
UGT1A1 drug- drug interactions between GS -9883 and probe drugs (ongoing)
GS-US-
141-1487, a Phase [ADDRESS_122316] of GS- 9883 on Renal Function as Assessed b y Markers of Glomerular 
Filtration Rate (ongoing)
GS-US-
311-1790, a Phase [ADDRESS_122317] of F/TAF FDC Tablet or GS -9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethiny l Estradiol (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 20 21October 2015GS-US-380- 1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug -Drug Interaction 
Potential between GS -9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed -Dose Combination (FDC) 
Tablets (ongoing)
GS-US-141- 1475, a Phase 2 Randomize d, Double- Blinded Study  of the Safety  and Efficacy  
of GS -9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + 
Emtricitabine/Tenofovir Alafenamide in HIV -1 Inf ected, Antiretroviral Treatment
-Naive 
Adults (ongoing)
Please refer to the GS -9883/F/T AF Investigators’ Brochure for further information about 
these
[IP_ADDRESS]. Phase [ADDRESS_122318] of food on the PK of GS- 9883.   Part D was a randomized, open -label, 
2-cohort, 3
-period, crossover PK study  evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS -9883 in healthy  subjects.
There was no difference in the overall incidence or ty pe of AEs when GS -9883 was administered 
in the fasted and fed states. There was no difference in the overal l incidence of AEs when 
GS-
9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Grade 3 or 4 AEs or SAEs, were reported in any  
cohort.
Increases in serum creatinine were observed in this study , presumabl y via inhibition of the renal 
transporter OCT2.  In the MAD cohorts (fasted), serum creatinine change at Day 14 ranged from 
0.05 mg/dL for the 5 mg cohort to 0 .18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), s ubjects received 100 mg GS- 9883 mon otherap y for 
7days and 100 mg GS -9883 with FTC/TAF for 7 day s, the mean serum creatinine change at 
Day 7 was 0.14 mg/dL following GS -9883 and 0.17 mg/d L following GS -9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS -9883.
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . Grade 3 laboratory  
abnormalities included 10 subjects with Grade 3 u rine dipstick tests for blood. All of these 
subjects were female, none of the lab s were considered b y the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laborator y 
abnormalities were observed.
Based on results in study GS- US-141- 1218, pharmacokinetic profile of GS -9883 was 
characterized b y rapid absorption with time to peak plasma concentrations (median t maxof 
cohorts) ranging between 1 and 4 hours following administration under fasted conditions. 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 21 21October 2015GS-9883 exposures were appropriatel y dose proportional following single dose 25-100 mg dose 
administration, with decreasing dose proportional at higher doses.  The half -life of GS -9883 was 
approximately  18hours, with no changes observed across studied dose range as evidenced by  
[CONTACT_10836] . A high -fat meal incr eased AUC infand C max (geometric mean, 
84% and 101%, respectively ) following 100 mg single dose administration. Steady  state was 
achieved after 4 -6days of once dail y dosing of GS -9883 with average accumulation ratios for 
AUC 24hrof
1.6.
Table1-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Following 
Single Doses of GS -9883 in Healthy Subjects (GS -9883 PK Analysis 
Set; Part A: Single Dosing)
GS-9883 PK 
Parameter
Mean 
(%CV)5mg
(N=6)25 mg
(N=6)50 mg
(N=6)100 mg
(N=6)300 mg
(N=6)600 mg
(N=6)
Cmax (ng/mL)691.2
(22.1)1618.3
(26.7)3965.0
(40.1)6998.3
(36.1)[ZIP_CODE].0 
(27.1)[ZIP_CODE].0
(7.5)
Tmax(hr)1.25 
(1.00 -1.50)2.00
(1.00 -3.00)3.00
(1.50 -4.00)2.25
(1.50 -3.00)3.50
(2.00 -6.00)3.5
(2.00 -4.00)
AUC inf 
(ng.hr/mL)[ZIP_CODE].7
(25.1)[ZIP_CODE].2 
(21.3)[ZIP_CODE].5 
(29.7)163028.2 
(24.3)355917.3 
(32.9)454446.8 
(19.9)
T1/2 (hr)18.51
(16.81 -19.99)18.08
(16.63 -19.64)16.72
(15.77 -17.11)18.90
(17.96 -20.05)18.14
(17.86 -20.53)17.89
(16.38 -19.52)
T1/2and T max: Median (Q1, Q3)
Table 1-2presents GS -9883 plasma PK parameters following administration of GS -9883 
(5,25, 50, 100, and 300 mg) once daily for 7 days . Following administration of either GS -9883 
(5,25, 50, 100, or 300 mg) once dail y for 7 days, the PK absorption profile observed on Day s 1 
and 7 was similar to that observed in Part A (SAD). The median T maxvalues ranged from 1.5 to 
2.5hours on Day  1 and 1.5 to 4.0 hours on Day 7. Linearit y was observed comparing GS -9883 
AUC and C maxon Day s 1 and 7 over the dose range of 25 to 50 mg. Stead y state levels of 
GS-9883 were achieved between Stud y Da ys 4 to 6 of do sing and maintained through Day 14. 
Accumulation is approximately  1.6-fold, which is consistent with the observed half -life of the 
GS-9883 (approximately  18 hours).
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 22 21October 2015Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by 
[CONTACT_10827]-9883 Dose Following Multiple -Dose Administration of GS -9883 
(Analysis Set: GS -9883 PK Part B: Multiple -Dose)
GS-9883 PK Param eter Mean
(%CV)aMultiple-Dose GS-9883
5mg
(N=6)25mg
(N=6)50mg
(N=6)100mg
(N=6)300mg
(N=6)
Day 1AUC 0-24 (hr*ng/mL)9033.6
(8.2)27,775.1
(28.3)58,371.4
(18.9)79,773.8
(18.9)180,714.3
(17.6)
Cmax(ng/mL)709.7
(9.5)2220.0
(35.6)4648.3
(18.7)6248.3
(26.8)13,716.7
(19.1)
Tmax(hr)1.50
(1.50, 1.50)1.75
(1.00, 3.00)1.50
(1.00, 2.00)2.50
(2.00, 3.00)2.50
(2.00, 4.00)
Day 7AUC tau (hr*ng/mL)14,392.0
(16.7)50,008.2
(26.6)89,710.1
(22.7)126,785.8 
(23.7)277,200.2 
(16.7)
Cmax(ng/mL)982.5
(7.9)3455.0
(24.1)6538.3
(17.6)9396.7
(20.8)19,900.0 
(21.2)
Ctau(ng/mL)400.83
(26.9)1322.00
(27.8)2241.67
(28.2)3145.00 
(26.1)6758.33 
(21.6)
Tmax(hr)1.50
(1.00, 2.00)3.00
(2.00, 3.00)1.75
(1.50, 2.00)1.75
(1.50, 3.00)4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)160.5
(19.0)182.2
(17.1)154.0
(15.9)158.5
(12.1)157.5
(22.6)
a Data are presented as mean (%CV), except for T max, and t½, which are presented as median (Q1, Q3)
Table 1-3presents the GLSM ratios and associated 90% CIs for the test (fed) versus reference 
(fasted) treatments for the primary  plasma PK parameters of GS -9883. Administration of a single 
dose of GS -9883 100 mg with food (high
-calorie/high -fat breakfast) increase d the GL SM values 
of C maxand AUC inf101% (90% CI of GL SM ratio 165.93% to 242.74%) and 84% (90% CI of 
GLSM ratio 152.05% to 222.59%), respectivel y. There were no apparent changes in clearance 
and t 1/2following administration with food, indicating that fo od enhanced the bioavailability  of 
GS-9883 by  [CONTACT_10837]/or absorption.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 23 21October 2015Table1-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic 
Parameters Following Single -Dose Administr ation of GS -9883 in the 
Fasted and Fed States (GS -9883 PK Analysis Set)
GS-9883 PK Param eter Mean (%CV)
% GLSM Ratio 
(90% CI)Test
GS-9883 100 m g Fed
(n=8)Reference
GS-9883 100 m g Fasted
(n=8)
AUC inf(hr*ng/mL) 214,146.3 (15.9) 117,777.1 (23.3) 183.97 (152.05, 222.59)
AUC last(hr*ng/mL) 209,259.9 (15.1) 115,681.7 (24.0) 183.58 (151.91, 221.86)
Cmax(ng/mL) 11,268.8 (15.1) 5885.0 (34.9) 200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
[IP_ADDRESS]. Phase 1b Proof of Concept
The first HIV -1 positive human subjects were dosed in the fasted state with 10 day s of GS -9883 
in study  (GS-US-141-1219).  Four cohorts of 5 subjects each were randomized 4:[ADDRESS_122319] frequentl y reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3subjects).  No other AE was reported in more than [ADDRESS_122320]. There was no 
increase in the incidence of AEs with increasing doses of GS -
9883.
The majority  of AEs were considered by  [CONTACT_10838]. A total 
of 2subjects experienced mild diarrhea that was considered related to study drug ( 1 in the 5 mg 
cohort, 1 in the 100 mg cohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study  drug were reported in any  cohort.
The majority of laboratory  abnormalities were Grade 1 or Grade 2 in severity . No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL 
(100 mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study  drug. One Grade [ADDRESS_122321]. An adverse eve nt of elevated CK was reported unrelated to
study  medication.
Based on PK information collected in study  GS-US-141- 1219, which was in line with PK 
observed in stud y GS -US-141-1218, the median IQ for each dose were calculated and ar e 
presented in the Table below.
GS-9883/F/T AF 
Protocol GS-US-380-1844 Final 
[COMPANY_009] Sciences, Inc. Original 
Table 1-4. Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Correspondi ng Protein-Adjusted IQ9s Values (GS-9883 PK Analysis 
Set) 
GS-9883 dose n Median (range) C1au,ss (ng!mL) Median (range) paiQ95• 
5mg 4 206.5 (146.0 to 342.0) 1.3 (0.9 to 2.1) 
25mg 4 797.5 (714.0 to 1900.0) 4.9 ( 4.4 to 11. 7) 
50mg 4 2170.0 (852.0 to 3020.0) 13.4 (5.3 to 18.6) 
100mg 4 4190.0 (3730.0 to 5970.0) 25.9 (23.0 to 36.9) 
a. The protein adjusted IQ95 (paiQ95) value is estimated based on steady-state Ctau values and the in vitro paiC95 value for 
wild-type HIV-1 (162 ng/ml). 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copi[INVESTIGATOR_014]/mL) are presented 
in Figure 1-1. 
Figure 1-1. 
G$-9883 5 mg (n= ): 
G$-9883 25 mg (n= ): 
G$-9883 50 mg (n= ): 
G$-9883 100 mg (n=): 
Placebo (n=): GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copi[INVESTIGATOR_014]/mL) (PP Analysis Set) 
• = GS-9883 5 mg 
0 = GS-9883 25 mg 
b. = GS-9883 50 mg 
0 = GS-9883 100 mg 
0 =Placebo 
BL 2 3 
3 3 3 
4 3 4 
4 4 4 
4 4 4 
4 4 4 4 7 8 
3 3 
3 4 4 
4 4 4 
3 4 4 
4 4 4 9 10 11 
Day 
3 3 3 
4 4 4 
4 4 4 
4 4 4 
4 4 4 14 
3 
4 
4 
4 
4 17 
3 
3 
4 
4 
4 
NOTE: Baseline value was the last available value collected prior to the time of tl1e ftrst dose of study drug. 2 
-1 
-2 
-3 
CONFIDENTIAL Page 24 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 25 21October 2015Mean viral load change on Day  11 was - 2.08 log 10in the 25 mg cohort, -2.06 log 10in the 50 mg 
cohort, and - 2.43 log 10in the 100 mg cohort. Time weighted average change from baseline at 
Day 11 (DAVG11) was -0.92 log 10in the 5 mg cohort, -1.33 log 10in the 25 mg 
cohort, -1.37 log 10in the 50 mg cohort and -1.61 log 10in the 100 mg cohort.  Viral suppression 
(HIV -1 RNA < 50copi[INVESTIGATOR_014]/mL ) was ever achieved by [CONTACT_10839] y (Day 17)by 1subject 
(25.0%) in the GS -9883 50 mg group and 2 subjects (50%) in the GS -9883 100 mg group.
[IP_ADDRESS]. Summary  of Phase 2 Study  (GS-US-141-1475)
Study  GS-US-141- 1475 is an ongoing Phase 2, randomized, double -blind, mult icenter, 
active -controlled study  to assess the safety  and efficacy  of a r egimen containing 
GS-9883+F/TAF versus dolutegravir (DTG)+F/TAF in HIV -infected, antiretroviral ther apy 
(ART) -naive adult subjects.
Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by  [CONTACT_10840]-1 RNA level ( ≤ 
100,000 copi[INVESTIGATOR_014]/mL , 100,000 copi[INVESTIGATOR_014]/mL 
to400,000 copi[INVESTIGATOR_014]/mL , or > 400,000 copi[INVESTIGATOR_014]/mL) at screening:
Treatment Group 1: GS-9883 75 mg + F/TAF (200/25 mg) + placebo -to-match DTG 
50mg once dail y
Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo -to-match GS -9883 
75mg once dail y
Interim data at Week 12 are summarized below.
  Data from the Week 24 primary  endpoint are 
included in the GS -9883/F/TAF Investigator’s Brochure.
[IP_ADDRESS]. Subject Disposition and Baseline Characteristics
A total of 98 subjects were rand omized and treated in the study : 65 subjects in the 
GS-9883+F/TAF group and 33 subjects in the DTG+F/TAF group . At the time of the Week 12 
data anal ysis, 2 subjects (2.0%) had prematurel y discontinued study  treatment, one in each 
treatment group; bo th subj ects were lost to follow-up.
Demographic and baseline characteristics were similar between the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and estimated glomerular 
filtration rate [eGFR] using the Cockcroft -Gault method [eGFR CG]) were similar between the 
2treatment groups ( Table 1-
4).
Median (Q1, Q3) baseline HIV -1 RNA was 4.45 (3.96, 4.79) log 10copi[INVESTIGATOR_014]/mL , with 82.7% of 
subjects having ≤ 100,000 copi[INVESTIGATOR_014]/mL  at baseline; 5 subjects had > 400,000 copi[INVESTIGATOR_014]/mL  at 
baseline ; 4 of these subjects were randomized to GS -9883+F/TAF and [ADDRESS_122322] was randomized 
to DTG+F/TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL, with 41.8% of 
subjects having ≥ 500 cells/μL  at baseline. M edian (Q1, Q3) baseline eGFR CGwas 
125.3 (105.7, 147.0) mL /min.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 26 21October [ZIP_CODE].2.3.5. Efficacy  Results
Virologic success at Week 12 when assessed using the US FDA snapshot algorithm, defined as 
plasma HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL , was similar between the 2 treatment groups as follo ws: 
GS-9883+F/TAF 93.8%; DTG+F/TAF 93.9% (stratum
-adjusted difference in percentages: 
−1.3%; 95% CI: −12.9% to 10.2%; p = 0.79).
Following initiation of study  drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean ( SD) ba seline CD4 cell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL ; DTG+F/TAF 507 (271.0) cells/μL ; p=0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS -9883+F/TAF +170 (150.0) c ells/μL ; DTG+F/TAF +173 (220.5) cells/μL  
(difference in L SM: 0; 95% CI : −76 to 76; p = 1.00).
Interim Virology Resistance Data
Through Week 12, no emergent drug resistance was detected.
[IP_ADDRESS]. Safety Results
Adverse Events
The overall incidence of treatment -emergent AEs was balanced between treatment groups as 
follows: GS
-9883+F/TAF 58.5%, 38 subjects; DTG+F/TAF 57.6%, 19 subjects) .The most 
common TEAEs (occurring in > [ADDRESS_122323]) by [CONTACT_110095]:
GS-9883+F/TAF: diarrhea and headac he (6.2%, 4 subjects each); and fatigue and nausea 
(3.1%, 2 subjects each)
DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects); and fatigue, 
flatulence, and furuncle (6.1%, 2 subjects each)
Most treatment -emergent AEs were Grade [ADDRESS_122324] (diabetic ketoacidosis); this event was also reported as an SAE, and 1 other SAE 
(appendicitis) was reported. Neither SAE was considered related to study  drug b y the 
investigator, resulted in study  drug discontinuation, or required interruption of study  drug, an
d 
both SAEs resolved.
The overall incidence of study  drug -related treatment -emergent AEs was balanced between 
treatment groups as follows: GS- 9883+F/TAF 12.3%, 8 subjects; DTG+F/TAF 15.2%, 
5subject s. Most study  drug -related treatment- emergent AEs were Gr ade 1 in severit y. Grade 2 
study  drug -related treatment -emergent AEs (somnolence a nd headache) were reported in 
1subject. No Grade 3 or 4 treatment -emergent AEs or treatment -emergent SAEs were 
consi dered related to study  drug.
No deaths, pregnancies, or AEs leading to premature study drug discontinuation were reported.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122325] 1 treatment- emergent laborat ory abnormality  (ie, at least 
1grade level increase from baseline in graded abnormality ) was similar between treatment 
groups as follows: GS -9883+F/TAF 70.3%, 45 subjects; DTG+F/TAF 75.0%, [ADDRESS_122326] 1 Grade 3 or 4 treatment -emergent laboratory abnormalit y 
was similar between treatment groups as follows: GS-
9883+F/TAF 10.9%, 7 subjects; 
DTG+F/TAF 12.5%, 4 subjects. Grade 4 treatment -emergent laboratory  abnormalities 
(creatine kinase) were reported in only  2subjects.
There were no clinicall y significant changes from baseline or differences between treatment 
groups in the median values for hematology , chemistry , or metabolic parameters. Changes from 
baseline in serum creatinine were similar between treatment groups. Median (Q1, Q3) changes in 
serum creatinine at Week 12 were as follows: GS -9883+F/TAF 0.11 (0.06, 0.16) mg/dL; 
DTG+F/TAF 0.14 (0.06, 0.24) mg/dL. Chang es from baseline in eGFR were similar between
treatment groups. Median (Q1, Q3) changes in eGFR at Week 12 were as follows: 
GS-9883+F/TAF −12.2 (−18.0, −6.4) mL/min; DTG+F/TAF −15.8 (−30.1, −9.5) mL/min.
1.3. Information about Emtricitabine (Emtriva®, FTC)
Emtricitabine ( 5-fluoro -1-[(2R, 5S) -2-(hydroxy methyl)-[1, 3] -oxathiolan -5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HI V. In HIV-infected adults, 
FTC is administered as a 200 mg QD dose concurrently  with other ARVdrugs. The 200 mg FTC 
capsule formulation was approved b y the US Food and Drug Administration (FDA) for 
marketing on 2 July 2003 and is available under the name [CONTACT_10881]®. In the European Union 
(EU), marketing authorization was granted for both the 200 mg Emtrivacapsule formulation 
and a 10 mg/mL Emtrivaoral Solution formulation on 24 October 2003, with indications for 
the treatment of HIV infection concurrently  with other antiretroviral drugs in bot h adult and 
pediatric patients.
Further information is available in the current Prescribing Informat ion for Emtriva®.
1.4. Information about Tenofovir alafenamide (TAF, GS -
7340)
Tenofovir alafenamide (GS- 7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HI V-1 reverse transcription. Tenofovir is metabolized 
intracellularl y to the active metabolite, tenofovir diphosphate (TFV -DP), a competitive inhibitor 
of HIV -1 reverse transcriptase (RT) that terminates the elon gation of the viral DNA chain. The 
intracellular metabolism of TAF and TFV are consistent with the 600- fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV.
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 28 21October [ZIP_CODE].4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) or
Fixed Dose Combination emtricitabine/tenofovir alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:
GS-US-120- 1101, a Phase 1/2 study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (50 mg and 150 mg) in HIV -infected subjects (compl eted)
GS-US-120- 0104, a Phase 1b study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (8 mg, 25 mg, 40 mg) in HIV infected subjects (completed)
GS-US-120-0107, a Phase 1, partially- blinded, randomized, placebo- and positive controlled 
study  to evaluate the effect of GS- 7340 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-120-0108, a Phase 1, open- label, parallel -design stud y to evaluate the 
pharmacokinetics of GS -7340 in subjects with severe renal impairment (completed)
GS-US-120-0109, a Phase 1 study  to evaluate the pharmacokinetics, metabolism and 
excretion of GS -7340 (completed)
GS-US-120-0114, a Phase 1, open- label, parallel -group, single dose study  to evaluate the 
pharmacokinetics of tenofovir alafenamide in subjects with normal and impaired hepatic 
function (completed)
GS-US-120- 0117, a Phase 1 single -dose study  evaluating the pharmacokinetic drug 
interaction potential between rilpi[INVESTIGATOR_10790] (completed)
GS-US-120- 0118, a Pharmacokinetic study  evaluating the drug interaction potential of
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in
healthy  subjects (completed)
GS-US-311- 1386, a Phase [ADDRESS_122327] of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in health y volunteers (completed)
GS-US-311- 0101, a Phase 1 healthy  volunteer study  evaluating the drug interaction potential
between once -daily  FTC/GS -7340 fixed -dose combination and efavirenz (EFV) or
COBI -boosted darunavir (DRV) (completed)
GS-US-
311-1088, a Phase 1, Relative Bioavailability  Study  of Emtricitabine/Tenofovir
Alafenamide Fixed Dose Combination Tablet to evaluate the formulation performance of
emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose combination tablets relative
to co- administration o f individual agents (completed)
GS-US-311- 1089, a Phase 3 study  of the safety  and efficacy  of FTC/TAF in HIV infected,
virologicall y suppressed patients (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122328] of food (high -calorie, high- fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GL SM ratio of the AUC lastof TAF when 
administered with a high -fat meal was 177% (90% CI : 166% to 188%), and the TAF C max
GLSM ratio was 84 .5% (90% CI:74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma C maxwhen administered with food was 
accompanied b y a delay in T max(increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions) . The exposures of TAF observed under fed or fasted conditions in this 
study  are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TAF (see investigator 
brochu re for further details). Therefore, the changes in TAF exposures when F/TAF is 
administered with food should not result in differences in efficacy  and thus are not clinicall y 
relevant. TAF can be administered without regard for food and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
1.4.2. Clinical Trials of FTC/TAF as part of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, coformulated into the E/C/F/T AF STR include: 
GS-US-292- 0101, a Phase 1 healthy  volunteer study  evaluating the relative bioavailability  of 
EVG, FTC, TFV, and COBI administered as 
E/C/F/TAF STR relative to E/C/F/TDF or TAF
(completed)
GS-US-292- 0103, a Phase 1 healthy  volunteer study  t
o evaluate the pharmacokinetics and 
relative bioavailabilit y of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg (STR) or 25 mg Single Agent (SA) (completed)
GS-US-292- 0102, a Phase 2 randomized, double -blinded study  of the safet y and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV -1 infected, antiretroviral treatment
-naive 
adults (ongoing)
GS-US-292-
0104 and GS -US-292-0111 , Phase 3 randomized, double -blinded study  of the 
safet y and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV -1 infected, 
antiretroviral treatment- naive adults ( ongoing)
GS-US-292-0109, a Phase 3 o pen-label study to evaluate s witching from a TDF-c ontaining 
combination regimen to a TAF -containing combination single tablet r egimen (STR) in 
virologicall y-suppressed, HIV -1 positive s ubjects (ongoing)
GS-US-292- 0112, a Phase 3 Open -label Safet y Study  of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenami de single -tablet Regimen in HIV -1 
positive patients with mild to moderate renal impairm ent (ongoing)
GS-US-
292-0117, a Phase 3, two- part stud y to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by  [CONTACT_10841]/Cobicistat/Emtricitabine /Tenofovir Alafenamide in HIV -1 positive, 
antiretroviral treatment-experienced adults (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 30 21October 2015GS-US-292-0119, a Phase 3 open - label study to evaluate s witching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TA F) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV-1 positive a dults
(ongoing)
GS-US-292-0106, a Phase 2/3, open -label study of the pharmacokinetics, safety , and 
antiviral activity  of the Elvitegravir /Cobicistat/Emtricitabine/Tenofo vir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV -1 infecte d antiretroviral treatment- naive 
adolescents (ongoing)
Study  GS-US-
292-0101 is a Phase 1 study  of 40 subjects evaluating the relative bioavailability  
oftwo different formulations of E/C/F/TAF STR, each with TAF dose of 25 mg or 40 mg, versus 
E/C/F/TDF STR or TAF 25 mg alone . Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs 
E/C/F/TDF regardless of formulation (monolay er or bi -layer). I n 
contrast, TAF exposures were ~2.2 -fold higher (and corres ponding tenofovir exposures ~ 3-fold 
higher) when administered as E/C/F/TAF (25mg) vs TAF single agent (SA) 25mg for both 
formulations of the 
E/C/F/TAF, likel y mediated by [CONTACT_10842] P -gp-mediated intestinal
secretion of 
TAF by [CONTACT_10843] .
Study  GS-US-292- 0103 is a completed Phase 1 healthy  volunteer study which evaluate dthe PK
and relative bioavailability  of the E/C/F/TAF STR relative to the individual components at TAF
doses of 10 (STR) or 25 mg SA. Results indicate that when dosed as the E/C/F/TAF 10 mg STR, 
TAF and TFV exposures were comparable to those observed with TAF 25mg dosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually  
dosed formulations. 
Study  GS
-US-292-0102 is an ongoing, randomized, active -controlled Phase 2 study , compares 
E/C/F/TAF (10 mg) versus Stribild®(STB, E/C /F/TDF) in treatment -naïve, HIV -1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated potent ant iviral efficacy  (HIV-1 RNA 
<
50copi[INVESTIGATOR_014]/mL) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the snapshot 
algorithm); in the E/C/F/TAF group, no patient had emergent resistance to 1 or more components 
of the E/C/F/TAF. Importantly , E/C/F/TAF demonstrated a potential be nefit over E/C/F/TDF in 
terms of renal and bone safet y: smaller median decreases in eGFR (mL /min) (at Week 48, 
E/C/F/TAF - 5.5 vs E/C/F/TDF -10.0 [P<0.001) and smaller median percentage decreases in 
BMD (at Week 48, spi[INVESTIGATOR_050] E/C/F/TAF - 1.00 vs E/C/F/TDF -3.37 [p<0.001], hip -0.62 
vs -2.39 [p<0.001]).
Studies GS -
US-292 -0104 and GS-US-292-0111 are ongoing , Phase 3 randomized, 
double- blinded studies of the safet
yandefficac yof E/C/F/TAF versus E/C/F/TDF in HI V-1 
infected, antir etroviral treatment -naive adults. The interim Week 48 key conclusions from pooled 
data showed that E/C/F/TAF once dai ly was noninferior to STB once daily when administered 
for48 weeks to HIV- infected, ART -naive adults, as asse ssed using the US Food and Drug 
Administration (FDA )-defined snapshot algorithm with H I
V-1 RNA < 50copi[INVESTIGATOR_014]/mL  
(E/C/F/TAF 92.4%; STB 90.4%; diff erence in percentages: 2.0%, 95% CI: - 0.7% to 4.7%). 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 31 21October 2015Administration of E/C/F/TAF resulted in > 90% lower plasma TFV and higher intracellular 
TFV-DP relative to STB.  E/C/F/TA F showed an improved renal and bone safe typrofile with 
significant ly less decline in hip and spi[INVESTIGATOR_9210], less increase in serum creatinine and reduction 
in estimated glo merular filtration rate (eGFR).
1.5. Information about GS -9883/emtricit abine/tenofovir alafe namide 
(GS-9883/F/TAF)
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
1.5.1. GS-US-141-1233: Relative Bioavailability of GS -9883, FTC, and TAF 
between GS -9883/F/TAF and GS -9883 + F/TAF
Study  GS-US-141-1233 is an ongoing Phase 1 , open -label, 2-cohort, multiple -period,
fixed -sequence, crossover study  conducted at a single center in the US to evaluate 1) the relative 
bioavailability  (BA) of 2 GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets 
compared with the GS -9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet adm inistered 
simultaneously  and 2) the effect of food on the PK of GS- 9883, FTC, and TAF when 
administered as GS -9883/F/TAF (75/200/25 mg and 50/200/25 mg) FDC tablets. 
Cohort [ADDRESS_122329] of GS -9883/F/TAF (75/200/25 mg) FDC 
tablet in a [ADDRESS_122330] of GS -9883/F/ TAF (50/200/25 mg) FDC tablet in a 4
-period sequence. 
The in- life portion of Cohort 1 is complete; preliminary  results are summarized below. The 
in-life portion of Cohort 2 is ongoing.
Cohort 1 Results:
Pharmacokinetic Results
Under fasted conditions, GS -9883 AUC infand C maxwere 27% and 31% higher, respectivel y, 
following GS -9883/F/TAF (75/200/25 mg) FDC administration than following 
administration of single -agent GS-9883 (75 mg ) with the F/TAF (200/25 mg) FDC . FTC and 
TAF exposure was similar following administration of GS -9883/F/TAF (75/200/25 mg) or 
single -agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC
. Compared with 
administration under fasted conditions, administration of theGS-9883/F/TAF 
(75/200/25 mg) FDC with a high
-fat m eal resulted in a 46% higher GS -9883 AUC infand a 
27% higher GS -
[ADDRESS_122331] of food on TAF and FTC exposure was similar to that 
previously  observed for F/TAF (Study  GS-US-311-1386) . GS-9883/F/TAF may  be taken 
without regard to food.   Based on these results, Cohort 2 was added to the study  via protocol 
amendment to evaluate the relative BA of the GS-9883/F/TAF (50/ 200/25 mg) FDC tablet 
compared with the single -agent GS-9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC 
tablet administered simultaneously .
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 32 21October 2015Safety Results
Of the 28 subjects included in the Safet y Anal ysis Set for Cohort 1, 12 subjects (43%) had at 
least [ADDRESS_122332] discontinued the 
study  due to an AE.
1.6. Information about abacavir/dolutegravir/lamivudine (ABC/DTG/3TC 
Triumeq®)
Formore detailed information, refer to the current Prescribing I nformation and local product 
labeling for abacavir/dolutegravir/la mivudine .
1.7. Rationale for t his Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide -
associated toxicities ar e increasingl y important as HIV -infected 
patients are often diagnosed earlier, initiate therapy  earlier, and look toward lifelong therapy  
(often greater than 50 years). Where patients have access to treatment, morbidity  and mortality  
are driven b y non –AIDS-associated comorbidities, which are observed earlier than in 
HIV-uni nfected age -matched controls despi[INVESTIGATOR_10791]. The contribution of 
specific nucleos(t)ides
, including abacavir and tenofovir disoproxil fumarate, to long -term 
morbidity  and mortality  is increasingl y important in this context.
The GS -9883/F/TA F FDC has the potential to offer a simple, once -daily regimen containing a 
second generation INSTI that provides a high barrier to resistance, does not require a boosting 
agent, and offers an effective and safer alternative to standard nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities. It could provide 
a FDC treatment that avoids the risk of hy persensitivity  reactions, would not contribute to an 
increased risk of cardiovascular events; could be us ed in 
patients with chronic hepatitis B or C 
infection or renal impairment, and that could be continued as patients age and confront 
non-HIV-related comorbidities.
The objective of this stud y is to evaluate the efficacy  of switching from a regimen of DTG a nd 
ABC/3TC or a Fixed dose combination (FDC) of ABC/DTG/3TC toa FDC of GS -9883/F/TAF
versus continuing DTG and ABC/3TC as the FDC ABC/DTG/3TC in virologically  suppressed 
HIV
-1 infected subjects as determined b y the proportion of subjects with virologic fa ilure 
(HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48. ABC/DTG/3TC was selected as the active 
comparator for this study as it is a second -generation integrase inhibitor-based, once- daily  fixed 
dose combination, and isa DHHS Guidelines preferred regimen that include s the 3TC/ABC 
backbone. Use of ABC/DTG/3TC as a comparator in this study  will therefore allow comparison
of two single tablet regiments containing second generation, unboosted INSTI s.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 33 21October [ZIP_CODE].8. Risk/Benefit Assessment for the Study
All patients with HI V-1 infection should receive effective antiretroviral therapy . Potential risks 
associated with all classes of ARVs include immune reconstitution sy ndrome, lipody strophy , and 
lactic acidosis with steatosis.  The risk of class effects is considered to be low.  I mportant 
identified risks appropriately  managed by  [CONTACT_110096]/exclusion criteria as well as through 
close clinical and laboratory  monitoring during the study , are as follows: hy persensitivity  
reaction to abacavir and allergy  to an y components of the tablets.  S ome observational studies 
have shown increased risk of cardiovascular disease with abacavir.  Interim data will also be 
reviewed b y an independent data monitoring committee.  Potential benefits may  include 
provision of a new antiretroviral therap y that is not currently available and which may  have 
fewer side effects than alternative therapi[INVESTIGATOR_014].  Other potential benefits include provisions of fixed 
dose combination therapy, and the knowledge that patient participation will contribute to the 
body  of knowledge of HIV therapi[INVESTIGATOR_014].
The overall benefit- risk assessment for GS -9883/F/TAF is favorable at this time.
1.9. Rationale for Dose Selection
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currentl y available as 
single agent capsules (EMTRI VA) and as a component of a number of fixed -dose combination 
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA) , and STRI BILD.
TAF
Based upon results of the Phase 1 Study  GS-US-120-0104, in which various doses of TAF 
(8mg, 25 mg, and 40 mg) were administered to HIV -infected subjects in 10 days of 
monotherap y, the range of exposure achieved with TAF 25 mg was chosen as the reference 
exposure. I n this study , TAF 25 mg resulted in near -maximal antiviral activity  and plasma TFV 
exposure > 90% low er relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF s ystemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with T AF 10 mg 
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safet y 
and efficacy  database exists. Specifically , TAF [ADDRESS_122333] on TAF exposure. Therefore, the dose of TAF 
25 mg is appropriate for the GS -9883/F/TAF FDC.
GS-9883
The dose of GS -9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table 1-5), in which HIV-1 -infected subjects were administered 5, 25, 50, or 100 mg doses of 
GS-9883 monotherap y under fasting conditions for 10 day s.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 34 21October 2015Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrations at Steady 
State Following GS -9883 Administration Under Fasting Conditions 
and Corresponding Protein -Adjusted IQ 95Values
GS-9883 dose nMedian (range) C tau,SS(ng/mL) Median (range) paIQ 95a
5 mg 4 206.5 (146.0 –342.0) 1.3 (0.9 –2.1)
25 mg 4 797.5 (714.0 –1900.0) 4.9 (4.4 – 12)
50 mg 4 2170.0 (852.0 –3020.0) 13 (5.3 –19)
100 mg 4 4190.0 (3730.0 –5970.0) 26 (23 – 37)
a The paIQ 95value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for wild -type HIV -1 
(162 ng/mL).
Source: Data on File
Single -agent GS -9883 was well tolerated atall doses admi nistered. The range of GS-9883 
plasma exposure at steady  state (C tau,SS) observed in the 50 -mg cohort correlated with protein 
adjusted 95% inhibitory  quotient (paIQ 95) values ranging from 5 .3to19, while the range of 
GS-9883 plasma exposure at stead y state (C tau,SS) observed in the 100 -mg cohort correlated with 
paIQ 95values ranging from 23 to 37 ( Table 1-5).
Based on PK/PD analy ses, exposure following a 75-mg dose of single- agent GS -9883 is 
expected to provide near -
maximal virologic response, with a predicted paIQ 95of approximately 
20, providing considerable coverage above the target concentration of 162 ng/mL (paI C95).
GS-9883 (75 mg) single agent coadministered with F/TAF (200/25 mg) is currentl y being 
evaluated in a Phase 2 study , GS-US-141- 1475 (GS -9883+F/TAF vs DTG+F/TAF). The 
Week 12 interim data from this study , suppor t the safet y and efficacy of GS -9883 exposures 
obtained with the 75 mg dose of the single agent .
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS -9883/F/TAF is being developed for use in Phase 3 studies. 
Preliminary  results from the relative bioavailability  (rBA) study  (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that GS -9883 plasma exposure was higher (with C max
and AUC infincrease of 31% and 27%, respectively) following administration of the FDC as 
compared with exposure following administration of GS
-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions
. The increase in GS -9883 exposures associated with the FDC 
form ulation results in an estimated mean paIQ 95of 24.3, compared to an estimated mean paIQ 95
of 19.2 for the GS -9883 (75 mg) single agent coadministered with F/TAF , in the fasted state.
In order to bridge exposures of GS -9883 in the FDC to the exposure observ ed with GS -9883 
75mg administered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study  GS-US-141- 1475, a lower strength GS -9883/F/TAF FDC is being 
developed for use in the Phase 3 studies. Comparability  of GS -9883 exposures will be confirmed 
in an rBA stud y of GS -9883/F/TAF (50/200/25 mg) and GS -9883 (75 mg) + F/TAF prior to 
initiation of dosing in the Phase 3 studies.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122334] ice (GCP), 
and all applicable regulatory  requirements.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 36 21October [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of switching from a regimen of DTG and ABC/3TC or a fixed dose 
combination (FDC) of ABC/DTG/3TC toa FDC of GS -9883/F/TAF versus continuing DTG 
and ABC/3TC as the FDC ABC/DTG/3TC in virologicall y suppressed HIV-1 infected 
subjects as determined by [CONTACT_110097] (HIV -1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48
The secondary  objectives of this study  are:
To evaluate the safet y, and tolerability  of the two treatment group s through Week 48
To evaluate the bone safety  of the two treatment group s as determined b y the percentage 
change from baseline in hip and spi[INVESTIGATOR_1928]  (BMD) through Week 48
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 37 21October [ZIP_CODE]. STUDY DESIGN
3.1. Endpoints
The primary  efficacy  endpoint is :
Theproportion of subjects with virologic failure (HIV-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL )at Week 48 
as defined b y the modified US FDA snapshot algorithm.
The secondary  endpoints of this study  include:
The propor tion of subjects with HI V-1 RNA < 50copi[INVESTIGATOR_014]/mL  at Week 48 as defined by  [CONTACT_110098]
The change from baseline in CD4+ cell count at Week 48
The percentage change from baseline in hip and spi[INVESTIGATOR_110075] 48
3.2. Study Design
This protocol desc ribes a randomized, double -blind, multicenter, active -controlled study  to 
evaluate the safet y and efficacy of switching to GS-9883/F/TAF FDC versus continuing 
DTG +ABC/3TC as the FDC ABC/DTG/3TC in HIV
-1 infected subjects who are virologically  
suppressed (H IV-1 RNA < 50 copi[INVESTIGATOR_014]/mL) on a stable regimen (of DTG + ABC/3TC or the FDC 
ABC/DTG/3TC) for ≥ 3 months prior to screening.
3.3. Study Treatments
Subjects who provide written informed consent and meet all eligibility  criteria will be 
randomized in a 1:1 ratio to one of the following two treatment groups :
Treatment Group 1: FDC of GS-9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25mg (GS -9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50mg/lamivudine 300 mg (ABC/DTG/3TC) admini stered orall y, once daily , without regard to 
food (n=260 )
Treatment Group 2: FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) QD + Placebo to match FDC of GS-9883 50 mg/ emtricitabine 
200mg/tenofovir alafe namide 25 mg (GS -9883/F/TAF) admini stered orally , once daily , without 
regard to food (n=260 )
3.4. Duration of Treatment
Subjects will be treated for at least 48 weeks. Subjects’ treatments will be unblinded after the last 
subject completes the Week 48visit and[COMPANY_009] completes the Week 48 analy sis. Subjects will 
continue to take their blinded study  drug and attend visits every  12 weeks until treatment 
GS-9883/Fff AF 
Protocol GS-US-380-[ADDRESS_122335] been unblinded . At the Unblinding Visit, subjects in a countiy where 
GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/TAF FDC 
in an open label extension phase for [ADDRESS_122336] of care. 
Figure 3-1. 
Screening 
:S JO da>'S prior 
lo Dayl Study Schema 
Week.tS•b 
Primary Endpoint 
Treatment Ann 1: S"·itch to FDC ofGS-9883 FI'OTAF • QD -Plac~bo to match FDC ABC DTG 3TC QD C\•260) 
Troumonr Ann 2: FDC ofA.BCD TC 3TC QD-Pbeebo ~ to match FDC ofGS-9883 FTCTAF QD (.:\•260) 
% :% Jfthyfti 
a. Following the Day 1 visit, subjects will be required to retum for study visits at Weeks 4, 8, 12, and then every 12 weeks 
through Week 48. 
b. After Week 48, subjects will continue to take their blinded study drug and attend visits every 12 V.'l!eks until treatment 
assignments have been tmblinded . Subjects' treatments will be tmblinded after the last subject completes the Week [ADDRESS_122337] of care. 
c. Once [COMPANY_009] Sciences provides unblinded treatment assignments to the Investigators, all subjects willretwn to the clinic 
(preferably within 30 days) for an Unblinding Visit. At the Unblinding Visit, subjects in a cotmtry where GS-9883/FffAF 
FDC is not available will be given the option to receive GS-9883/F ffAF FDC in an open label extension for [ADDRESS_122338]. 
d. Subjects who complete the study through the Unblinding Visit and do not continue on the open-label GS-9883/F/TAF FDC 
extension phase will be required to retwn to the clinic 30 days after the completion of study dmgs for a 30-Day Follow-Up 
Visit. 
3_5_ Biomark er Testing 
3_5_1_ Biomark er Samples for Optional Pharmacogenomic Research 
[COMPANY_003] 
CONFIDENTIAL Page 38 21 October 2015 
GS-9883/F/T AF 
Protocol GS-US-380-1844 
[COMPANY_009] Sciences, Inc. 
PD 
3.5.2. Additional Sample Storage Final 
Original 
For subjects who provide additional consent, res idual blood and urine samples taken throughout 
the study will be stored. Stored samples may be used by [CONTACT_10845], and HIV disease and its associated conditions, or to 
provide additional safety data. At the conclusion of this study, these samples may be retained in 
storage by [CONTACT_10846] a period up to 15 years. 
CONFIDENTIAL Page 39 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122339] meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2)Age 18years
3)Currently  receiving an a ntiretroviral regimen of DTG + ABC/3TC , or ABC/DTG/3TC FDC
for ≥ 3 months prior to the screening visit
4)HIV RNA < 50 copi[INVESTIGATOR_014]/mL at the screening visit
5)Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant)
6)Adequate renal function:
Estimated glomerular filtration rate ≥ 50 mL/min (
≥ 0.83 mL/sec) according to the 
Cockcroft -Gault formula {2202}:
a)Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
        (140 –age in years) (wt in kg)          CLcr (mL /sec)
72(serum creatinine in umol/L )0.6786
b)Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
        (140 –age in years) (wt in kg)            0.85 CLcr (mL /sec)
72(serum creatinine in umol/L )0. 6786
7)Hepatic transaminases (AST and ALT) 5upper limit of normal (ULN)
8)Total bilirubin 1.5mg/dL (26 umol/L) , or normal direct bilirubin
9)Adequate hematologic function (absolute neutrophil count ≥750/mm3(≥ 0.75 GI/L); 
platelets ≥50,000/mm3(≥50 GI /L); hemoglobin ≥ 8.5 g/dL (≥85 g/L) )
10)Serum amy lase ≤ 5 × ULN (subjects with serum amy lase > 5 ×ULN will remain eligible if 
serum lipase is ≤ 5
×ULN)
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 41 21October 201511)Females of childbearing potential must agree to utilize protocol recommended highl y 
effective contraceptive methods or be non- heterosexually  active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study  period, and 
for [ADDRESS_122340] dose of study  drug .
a)Female subjects who utilize hormonal contraceptive as one of their birth control methods 
must have used the same method for at least 3 months prior to study  drug dosing.
12)Male subjects who engage in heterosexual intercourse must agree to use protocol specified 
method(s) of contracepti on (as described in Appendix 6
) throughout the study period and for 
[ADDRESS_122341] dose of study  drug.
13)Male subjects must agree to refrain from sperm donation from first study  drug dose until at 
least [ADDRESS_122342] study  drug dose
14)Life expectancy  ≥ 1 y ear
15)Currently  on the first or second antiretroviral regimen with documented plasma HIV -1 RNA 
< 50 copi[INVESTIGATOR_014]/mL on a stable regimen (or undetectable HIV- 1 RNA level according to the local 
assay  being used if the limit of detection is ≥ 50 copi[INVESTIGATOR_014]/mL ) for 
≥ 3 months preceding the 
Screening visit.
Prior changes in antiretroviral regimen are onl y allowed due to tolerabilit y issues or for 
regimen simplification. U nconfirmed virologic elevation sof ≥ 50 copi[INVESTIGATOR_014]/mL  (transient 
detectable viremia, o r “blip”) prior to screening areacceptable. If the lower limit of detection 
of the local HIV -1 RNA assay  is <50 copi[INVESTIGATOR_014]/mL (eg, <20 copi[INVESTIGATOR_014]/mL), the plasma HIV -1 
RNA level cannot exceed 50 copi[INVESTIGATOR_014]/mL  on twoconsecutive HIV -1 RNA tests.
16)Have no documented or suspected resistance to FTC, T FV, DTG, ABC or 3TC including ,but 
not limited ,to the reverse transcriptase resistance mutations K65R and M184V/I
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2)Subjects experiencing decompensated cirrhosis (e .g, ascites, encephalopathy , or variceal 
bleeding)
3)Have been treated with immunosuppressant therapi[INVESTIGATOR_10793] 
3months of study  screening, or expected to receive these agents or s ystemic steroids during 
the study  (e.g, corticosteroids, immuno globulins, and other immune -or cy tokine -based 
therapi[INVESTIGATOR_014] )
4)Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 42 21October [ZIP_CODE])A history  of or ongoing malignancy  (including untreated carcinoma in -situ) other th an 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive cutaneous 
squamous carcinoma. Subjects with biopsy -confirmed cutaneous KS are eligible, but must 
not have received an y systemic therap y for KS within 30 days of Day  1 and a re not 
anticipated to require s ystemic therap y during the study
6)Active, serious infections (other than HIV- 1 infection) requiring parenteral antibiotic or 
antifungal therap y within 30 days prior to Day  1
7)Participation in any other clinical trial , including observational studies,  without prior 
approval from the sponsor is prohibited while participating in this trial
8)Any other clinical condition or prior therapy  that, in the opi[INVESTIGATOR_2511] I nvestigator, would 
make the subject unsuitable for the stud y or unab le to comp ly with the dosing requirements
9)Any known allerg ies to the excipi[INVESTIGATOR_10794] -9883/F/TAF FDC or ABC/DTG/3TC FDC 
tablets
10)Females who are pregnant (as confirmed b y positive serum pregnancy  test)
11) Females who are breastfeeding
12)Subjects receiving ongoing therap y with an y of the following medications in the table below, 
including drugs not to be used with FTC, TAF, GS -9883, DTG , ABC and 3TC
Drug Class Agents Disallowed *
Antiarrhythmic Agent Dofetilide
Anticonvulsants Phenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_10795], Rifapentine
Antiretrovirals Any antiretroviral drug that is not part of the study regimen
GI Motility Agents Cisapride
Herbal /Natural Supplements St. John’s Wort, Echinaccea
* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study.
13)Acute hepatitis in the 30 day s prior to study  entry
14) Chronic Hepatitis B Virus (HBV) infection, as determined b y either: 
a)Positiv e HBV surface antigen and negative HBV surface antibod y, regardless of HBV 
core antibod y status, at the screening visit
b)Positive HBV core antibody  and negative HBV surface antibody , regardless of HBV 
surface antigen status, at the screening visit
15)Active tuberculosis infection
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122343] using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any  other subject. The 
subject number assignment and randomization may be perform ed up to [ADDRESS_122344] 
eligibility  has been confirmed.
Su
bjects will be randomized in a 1 :1ratio to Treatment Group 1 or Treatment Group 2.
The I WRS will assign study  drug bottle numbers of blinded FDC of GS-9883 /F/TAF +Placebo 
to match FDC of ABC/DTG/3TC, orFDC of ABC/DTG/3TC + Placebo to match FDC of 
GS-
9883/F/TAF at each study  visit for each subject. 
5.1.1. Procedures for Breaking Treatment Codes
In the event of a medical emergency  where breaking the blind is required to provide medical care 
to the subject, the investigator may  obtain treatment assignment direc tly from the IWRS system 
for that subject. [COMPANY_009] strongl y recommends but does not require that the investigator contact 
[CONTACT_110099]. Treatment assignment should remain 
blinded unless that knowledge is necessary  to determine subject emergency medical care. The 
rationale for unblinding must be clearly explained in source documentation and on the electronic 
case report form ( eCRF), along with the date on which the treatment assignment was 
obtained. The investigator is requested to contact [CONTACT_10849] .
Blinding of stud y treatment is critic al to the integrity  of this clinical trial and therefore, if a 
subject’s treatment assignment is disclosed to the investigator, the subject will have study  
treatment discontinued. All subjects will be followed until study  completion unless consent to do 
sois specificall y withdrawn by [CONTACT_423].
[COMPANY_009] Drug Safet y and Public Health (DSPH) may independentl y unblind cases for expedited 
reporting of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs).
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 44 21October [ZIP_CODE].2. Description and Handling
5.2.1. Formulation
[IP_ADDRESS]. GS-9883/Emtricit abine/Tenofovir alafen amide (GS -9883/F/TAF) 
50mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir alafenamide 25 mg tablets are capsul e-shaped, 
film-coated purplish -brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tab let. Each tablet core contains 5 0 mg of GS -9883, 200 mg of emtricitabine, 
and 25 mg of tenofovir alafenamide . In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcry stalline cellulose. The 
tablet cores are film- coated with iron oxide red, ironoxide black ,polyethylene gl ycol, pol yvinyl 
alcohol, talc, and titanium dioxide .
The placebo to match (PTM) GS- 9883/F/TAF tablets are capsu
le-shaped, film -coated 
purplish- brown, debossed with "GSI" on one side of the tablet and "98 83" on the other side and 
are identical in phy sical appearance to GS-9883/F/TAF tablets. The placebo tablets contain 
microcry stalline cellulose, lactose monohy drate, croscarmellose sodium and magnesium stearate. 
The tablet cores are film -coated with iron oxide red ,iron oxide black ,polyethylene gl ycol, 
polyvinyl alcohol, talc, and titanium dioxide .
[IP_ADDRESS]. Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600mg/50 mg/300 mg and Placebo to Match Tablets
Abacavir 600 mg/Dolutegravir 50 mg/Lamivudine 300 mg tablets are oval, film coated purple, 
and debossed with “572 Tri” on one side. Each tablet core contains 600 mg of abacavir, 50 mg of 
dolutegravir, and 300 mg of lamivudine. In addition to the active ingredients, the 
ABC/DTG/3TC tablets contain the inactive ingredients D -mannitol, magnesium stearate, 
microcry stalline cellulose, povidone, and sodium starch gl ycolate. The tablet cores are film 
coated with iron oxide black, iron oxid e red, polyethylene gl ycol, poly vinyl alcohol , talc, and 
titanium oxide.
The PTM ABC/DTG/3TC tablets are oval, film coated purple, and debossed with “572 Tri” on 
one side. The placebo tablets are identical in ph ysical appearance to ABC/DTG/3TC tablets. The
placebo tablets contain microcry stalline cellulose, lactose monohy drate, croscarmellose sodium 
and magnesium stear ate.  The tablet cores are film- coated with 
iron oxide black, iron oxide red, 
polyethylene gly col, polyviny l alcohol , talc, and titanium oxid e.
5.2.2. Packaging and Labeling
[IP_ADDRESS]. GS-9883/Emtricitabine/Tenofovir alafenamide (GS-9883/F/TAF) 
50mg/200 mg/25 mg and Placebo to Match Tablets
GS-9883/F/TAF tablets and PTM GS -9883/F/TAF tablets are packaged in white, high densit y 
polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and pol yester 
packing material.  Each bottle is enclosed with a white, continuous thread, child -resistant 
polypropylene screw cap with an induction -sealed and aluminum- faced liner.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 45 21October 2015Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations
[IP_ADDRESS]. Abacavir/Dolutegravir/Lamivudine (ABC/DTG/3TC Triumeq®) 
600mg/50 mg/300 mg and Placebo to Match Tablets
ABC/DTG/3TC tablets and PTM ABC/DTG/3TC tablets are packaged in white, high densit y 
polyethylene (HDPE) bottle s. Each bottle contains 30 tablets and silica gel desiccant . Each bottle 
is enclosed with a white, continuous thread, child -resistant poly propylene screw cap with an 
induction
-sealed and aluminum -faced liner.
Study  drug(s) to be distributed to centers in t he US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or oth er loca l regulations.
5.2.3. Storage and Handling
Study  drug GS-9883/F/TAF FDC ,ABC/DTG/3TC FDC and placebo -to-match tablets for both 
FDCs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted 
between 15°C and 30°C (59°F and 86 °F). 
Storage conditio ns are specified on the label. Until 
dispensed to the subjects, all bottles of study  drugs should be stored in a securely  locked area, 
accessible only  to authorized site personnel.
To ensure the stabilit y and proper identification, study dr ug(s) should not be stored in a container 
other than the container in which they  were supplied.
Consideration should be given to handling, preparation, and disposal through measures that 
minimize drug contact [CONTACT_10850] . Appropriate precautions should b e followed to avoid direct 
eye contact [CONTACT_10851].
5.3. Dosage and Administration of GS-9883/Emtricitabine/Tenofovir alafenamide 
and Abacavir/Dolutegravir/Lamivudine
Study  drug GS-9883/F/TAF FDC , ABC/DTG/3TC FDC andplacebo -to-match tablets for both 
FDCs will be provided by  [CONTACT_10869].
Treatment Group1: FDC of GS- 9883 50 mg/ emtricitabine 200 mg/ tenofovir alafenamide 
25mg (GS -9883/F/TAF) + Placebo to match FDC of abacavir 600 mg/ dolutegravir 
50mg/lamivudine 300 mg (ABC /DTG/3TC) administered orall y, onc e daily , without regard to 
food
Treatment Group2:FDC of abacavir 600 mg/dolutegravir 50 mg/ lamivudine 300 mg 
(ABC/DTG/3TC) + Placebo to match FDC of G
S-9883 50 mg/ emtricitabine 200 mg/ tenofovir 
alafenamide 25 mg (GS -9883/F/TAF) administered orall y, once daily, without regard to food
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122345] be accounted for b y the stud y monitor prior to destruction 
or return .
5.4. Prior and Concomitant Medications
The use of medications for the treatment of HIV, other than study  drug, is prohibited.
Medications listed in the following table and use of herbal/natural supplements are exc luded 
or should be used with caution while subjects are participating in the stud y.  Subjects will 
refrain from consumption of grapefruit juice and Seville orange juice throughout 
participation in the study .
Table5-1. Prior and Concomitant Medications
Drug Class Agents Disallowed*Use Discouraged and To Be Used With 
Caution
Acid Reducing Agents
Antacids
Buffered medications Concentration of study drug may 
decrease w ith antacids. Subjects may not 
take antacids (eg, Tums or Rolaids); the 
ulcer medication sucralfate (Carafate); or 
vitamin or mineral supplements that 
contain calcium, iron or zinc for a 
minimum of 2 hours before and 6 hours 
after any dose of study drug.
Antiarrhythmic Agent Dofetilide
AnticonvulsantsPhenobarbital, Phenytoin, 
Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_10795], Rifapentine
AntiretroviralsAny antiretroviral drug that is not part of 
the study regimen
GI Motility Agents Cisapride
Herbal/Natural 
SupplementsSt. John’s Wort, Echinaccea
Oral Hypoglycemic AgentMetformin : close monitoring is 
recommended. A dose adjustment of 
Metformin may be necessary .Limit total 
daily doses of Metformin to 1000mg 
when initiating study medication or if 
initiating metformin while on study drug .
* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study. 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122346] notify  [COMPANY_009] Sciences as soon as he/she is aware of the use o f the excluded 
medication.
5.5. Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP.
This includes acknowledgement of receipt of each shipment of IMP(quantity  and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study  Drug accountability records will be provided to each stud y site to:
Record the date received and quantity  of IMP kits
Record the date, subject numb er, subject initials, the IMP kit number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1. I nvestigational M edicinal Product Return or Disposal
Study  drug return and disposa l will be performed as outlined in Section 9.1.7 .
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122347] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the I nvestigator to ensure that subjects are eligible for study  prior to
enrollment. Please refer to Section 6.2.2 fordetails about randomization and treatment 
assignment .
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened within 30-days before Day 1todetermine eligibility  for participation in 
the study . The following will be performed and documented at screening:
Obtain written informed consent
Obtain medical history  including history  of HIV -1 disease -related events, smoking history
and prior medications within 30days of the screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supi[INVESTIGATOR_050]
Height
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], an d temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinaly sis
Blood sample collection for the following laboratory  anal yses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, the 
subject will not be enrolled
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 49 21October 2015Chemistry  profile: alka line phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, 
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN) 
and TSH .
Estimated glomerular filtration rate according to the Cockcroft -Gault formula:
■Male: (140 –age in years) (wt in kg) CLcr (mL /min)
72(serum creatinine in mg/dL)
          (140 –age in years)  (wt in kg)        CLcr (mL /sec)
72(serum creatinine in umol/L) 0.6786
■Female: (140 –age in years) (wt in kg) 0.85  CLcr (mL/min)
72(serum creatinine in mg/dL)
          (140 –age in years)  (wt in kg)        0.85 CLcr (mL /sec)
72(serum creatinine in umol/L) 0. 6786
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV -1 RNA
Hepatitis B virus surface antigen serology  (HBsAg)
Hepatitis B surface antibody  (HBsAb)
Hepatitis B virus core antibody  (HBcAb)
Hepatitis C virus (HCVAb) serology . Subjects who are HCVAb positive will have a 
HCV RNA test performed.
Review of adverse event s and concomitant medications
Subjects meeting all of the inclusion crit eria and none of the exclusion criteria will return to the 
clinic within 30-daysafter screening for Day  [ADDRESS_122348] all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse e vents case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history  eCRF. See 
Section 7Adverse Events and Toxicity  Management for additional details.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122349] complete all 
study  procedures , except DXA, before being administered the stu dy drug:
DXA Scan (spi[INVESTIGATOR_35632]) . For subjects in [LOCATION_013] , DXA scans will not be performed.
The DXA scan will be performed on subjects once eligibility  is confirmed. The scan may  
be performed prior to or within 24 hours of the Day 1 Visit.
Review of AEs a nd changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
12-lead ECG performed supi[INVESTIGATOR_050]
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module , Work Productivity  
and Activity  Impairment Questionnaire (WPA I) and Pi[INVESTIGATOR_10797] (PSQ I) 
to be completed b y the subject.  Subject is to read questionnaire b y himself/herself and 
write/mark answers directly  onto questionnaires.
Urine collection for the following laboratory  procedures:
Urinaly sis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta -2
microglobulin
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate
Urine storage sample for possible additional clinical testin g
Blood sample
collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phos phorus, magnesium, potassium, sodium, uric acid, and am ylase 
(reflex lipase testing is performed in subjects with total amy lase 1.5ULN ) and TSH
GS-9883/F/T AF 
Protocol GS-US-380-1844 
[COMPANY_009] Sciences, Inc. Final 
Original 
-Metabolic assessme nts: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and 
triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the 
subject must retum within 72 hours in a fasted state to draw blood for the metabolic 
assessments. 
-Estimated glomemlar filtration rate according to the Cockcroft -Gault f01mula 
- Hematology profile: complete blood cmmt (CBC) with differential and platelet cmmt 
-Plasma HIV-1 RNA 
-CD4+ cell count 
-Evaluatio ns of inflammation and immlme activation, may include but not limited to 
cystatin C, IL-6, hs-CRP, d-dimer, sCD14 and sCD163 
-Evaluatio ns of platelet function, including but not limited to soluble glycoprotein VI 
(sGPVI), P-selectin, and soluble CD40 ligand. 
-Plasma storage sample for safety, virology, or PK testing 
-Whole blood sample for potential HIV DNA genotypi[INVESTIGATOR_007] 
• Optional blood sample collection for the following laboratory analyses if 
pharmaco genomics consent is obtained 
I 
I 
I 
I 
6.3. Randomization 
Once eligibility has been confmned and prior to or during the Day [ADDRESS_122350] using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be perf01med up to [ADDRESS_122351] 
eligibility has been confi1med. 
CONFIDENTIAL Page 51 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 52 21October [ZIP_CODE].4. Treatment Assessments (Week 4 -48)
The following evaluations are to be completed at the end of Weeks 4,8, 12, 24, 36, and 48 unless 
otherwise specified .
Study  visits are to be completed within ± 2 day s of the protocol -specified visit date based on the 
Day 1 visit through Week 12 and completed within ± 6 day s of the protocol -specified visit date
through Week 36, unless otherwise specified.  The visit window at Week 48 will be ± 6 weeks of 
the protocol -
specified visit date, and t hese clinical visit window scoincide with the Week 48 
statistical analy sis window for HIV- 1 RNA .
Regularly  scheduled eva luations will be made on all subjects whether or not they  continue to 
receive study  drug.
Review of AEs and changes in concomitant medications
DXA scans (spi[INVESTIGATOR_35632]) for all subjects who are on study  drug(Weeks24and 48 
±10days). For subjects in German y, DXA scans will not be performed.
Complete physical examination (Weeks24 and 48) (urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom -directed phy sical e xamination as 
needed
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
12-lead ECG performed supi[INVESTIGATOR_050] 
(Weeks24and 48)
Short Form 36 Health Survey  (SF-36), HIV Sy mptoms Distress Module , Work Productivity  
and Activity  Impairment Questionnaire (WPA I) and Pi[INVESTIGATOR_10797] (PSQ I) 
to be completed b y the subject at Weeks 4, 12and [ADDRESS_122352] is to read questionnaire b y 
himself/herself and write/mark answers directl y onto questionnaires.
Urine collection for the following laboratory  procedures:
Urinaly sis
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta -2
microglobulin . (Weeks 24 and 48)
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test
. If the test is positive, the subject will be 
discontinued
Urine storage sample for possible additional clinical testing
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 53 21October 2015Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin , direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total amy lase1.5ULN). 
At Weeks 12, 24 and 48, anal yses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry  profile. At Weeks 24 and 48, TSH will also 
be anal yzed.
Metabolic assessments: Fasting (no food or drinks, except wate r, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24, and 48)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HI V-1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation, may includ ebut not limited to 
cystatin C, IL -6, hs- CRP, d -dimer, sCD14 and sC D163 (Weeks 24 and 48)
Evaluations of platelet function, may includ ebut not limited to soluble glycoprotein VI 
(sGPVI), P -selectin, and soluble CD40 ligand (Weeks24 and 48)
Plasma storage sample for safet y, virology ,or PK testing
Pharmacokinetic Blood Collection for subjects who are on stud y drug . Details of 
pharmacokinetic blood sampling procedures and sample management will be documented in 
the Pharmacokinetic Sample Collection, Processing, Storage, and Shipment Manual .
Single Anytime ,Troughand Post Dose PK Sample for all Subjects on Study Drug :
■ S ubjects will have a single anytime pre or post -dose PK blood sample atWeeks8, 24 
and 36 .
■Observed dosing at the clinic: Subjects will have a trough PK 
blood sample collected 
between 20- 28hours following their last dose at Weeks4 and 12. Subjects must be 
instructed to not take their study  drugs on the morning of their visit for the trough 
sample collection .   Subjects will then take an observed dose of study  drug at the 
clinic.  A single post dose PK blood sample wi ll be collected between 1 and 4 hours
GS-9883/F/T AF 
Protocol GS-US-380-[ADDRESS_122353] 
will not be instmcted to change their dosing time to accommodate this trough PK 
draw. 
• Dosing diaries will be collected from subjects for the single anytime PK and trough 
PK collection. If a dosing diaty is not retumed the site may ask the subject for the 
time of the last dose and if it was taken with or without food. 
-Optional Pharmacokinetic (PK) Substudy: 
• PD 
• Provide subject dosing diaty to all subjects. (Weeks 4, 8, 12 and 24) 
• Document study dmg dispensation and accountability for all study mugs dispensed. 
• Subjects who meet the criteria for virologic failme will be managed according to the 
Manageme nt ofVirologic Rebound Section 6.13.1 and 6.13.2. 
6.5. Treatment Assessments (Post Week 48 until the Unblinding Visit) 
6.5.1. Post Week [ADDRESS_122354] been unblinded, at which point they will retum for an 
Unblinding Visit (refer to Section 6.5.2) Study visits are to be completed within± 6 days of the 
protocol-specified visit date unless othetwise specified. 
CONFIDENTIAL Page 54 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122355] of care .
Review of AEs and changes in concomitant medications
Symptom -directed phy sical examination as needed
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinaly sis 
Urine albumin, urine creatinine, urine protein, retinol binding protein and beta -2
microglobulin .(Every 24 weeks)
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will be 
discontinued.
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bili rubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects with total am ylase 1.5ULN). 
Every  24 weeks, analy ses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry  profile. I n addition, TSH will also be 
analyzed every  24 weeks.
Metabolic assessments: Fasting (no food or d rinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 weeks)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma H IV-1 RNA
CD4+ cell count
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 56 21October 2015Evaluations of inflammation and immune activation , including but not limited to cy statin
C, IL-6, hs- CRP, d -dimer, sCD 14 and sCD163 (Every 24 weeks)
Evaluations of platelet function, including but not limited to soluble gly coprotei n VI 
(sGPVI), P -selectin, and soluble CD40 ligand (Every 24 weeks)
Plasma storage sample for safet y, virology, or PK testing
Document study  drug dispensation and accountability  for all study  drugs dispensed.
Subjects who meet the criteria for virologic failure will be managed according to the 
Management of V irologic Rebound Section 6.13.1. and6.13.2
6.5.2. Unblinding Visit
Once [COMPANY_009] Sciences provides unblinded treatment assignments to the Investigators, all subjects 
will return to the clinic (within 30 days± 6 day s) for an Unblinding Visit . At the Unblinding 
Visit , subject sin a country where GS -9883/F/TAF FDC is not available will be given the option 
to receive GS-9883/F/TAF FDC in an op en label extension phase for [ADDRESS_122356] .
Subjects who receive the open -label GS-9883/F/TAF FDC will r eturn for study  visits every  
12weeks.
Subjects 
who choose to not receive the open label GS- 9883/F/TAF FDC will be required to 
return to the clinic for a 30-Day Follow -up visit following the Unblinding Visit. Subjects who 
have discontinued drug study  prior to the Unblinding Visit wi ll not be eligible fo r the open -label 
rollover extension; these subjects will be asked to continue attending the scheduled study  visits 
through the Unblinding Visit and discontinue the study  after the Unblinding Visit.
The following will be performed at the Unblinding Visit:
Review of AEs and changes in concomitant medications
DXA scans (spi[INVESTIGATOR_35632]) for all subjects who are on study  drug(±
10days) . For subjects in 
German y, DXA scans will not be performed.
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
12-lead ECG performed supi[INVESTIGATOR_110076]-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 57 21October 2015Urine collection for the following laboratory  procedures:
Urinaly sis
Uurine a lbumin, urine creatinine, urine protein, retinol binding protein and beta -2
microglobulin.
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subje ct will not be 
able to participate.
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bi lirubin, total protein, albumin, L DH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, phosphorus, magnesium, potassium, sodium, uric acid, and am ylase 
(reflex lipase testing is performed in subjects with total amy lase 1.5ULN), and TSH
Metabolic assessments: Fasting (no food or d rinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platel et count
Plasma HIV -1 RNA
CD4+ cell count
Evaluations of inflammation and immune activation , may  includ ebut not limited to 
cystatin C, IL -6, hs- CRP, d -dimer, sCD14 and sCD163
Evaluations of platelet function, including but not limited to soluble 
glycoprotein VI 
(sGPVI), P -selectin, and soluble CD40 ligand
Plasma storage sample for safet y, virology , orPK testing
Document study  drug dispensation , if applicable, and accountability  for all study  drugs 
dispensed
Subjects who wish to continue in the Open-Label Rollover extension study  will receive open 
label GS -9883/F/TAF .
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122357] will be asked to continue attending the scheduled study visits 
through the Unblinding Visit.
At the Early Study Drugs Discontinuation Visit, any evaluations showing abnormal results 
indicating that there is a possible or probable causal relationship with the study drug , 
will
be repeated weekly (or as often as deemed prudent by [CONTACT_737]) until the 
abnormality is resolved, returns to Day 1, or is otherwise explained.
The following evaluations are to be completed at the Earl y Study Drugs Discontinuation Visit:
Review of AEs and changes in concomitant medications
DXA scan required (spi[INVESTIGATOR_35632]) for all subjects who are on stud y drug(±10days) if last 
scan was acquired > 12 weeks from the date of the ESDD Visit. For subjects in German y, 
DXA scans will not be performed.
Complete phy sical examination (urogenital/anorectal e xams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supi[INVESTIGATOR_050]
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinal ysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and
amylase (reflex lipase testing is performed in subjects with total amy lase 1.5ULN), 
and TSH
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 59 21October 2015Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage sample for safet y, virology , or PK testing
HIV-1 genot ype/phenot ypetesting for subjects with  virologic failure
Drug accountability
6.6.2. [ADDRESS_122358] one subsequent visit after the Early Study Drug Discontinuation Visit will notbe 
required to complete the 30 -Day Follow -Up Visit.
For the purpose of scheduling a 30 -Day Follow -Up Visit, a  6 days window may  be used. 
Thefollowing evaluations are to be completed at the 30- Day Follow -Up Visi t:
Review of AEs and changes in concomitant medications
Symptom -directed phy sical examination
Vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature), including 
weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 60 21October 2015Blood sample collection for the following laboratory  anal yses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT , total bilirubin, direct and 
indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, and 
amylase (reflex lipase testing is performed in subjects w ith total amylase 1.5ULN).
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
At the 30 -Day Follow -Up Visit, any  evaluations showing abnormal results believed to be a 
reasonable possibility  of a causal relationship with the study  drugs will be repeated weekl y (or as 
often as deemed prudent by  [CONTACT_737]) until the abnormality  is resolved, returns to 
baseline, or is otherwise explained. 
6.7. Criteria for Discontinuation of Study Treatment
Study  medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
ability  tocontinue study -specific procedures or is considered to not be in the subject’s best 
interest
Lack of efficacy
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 6
Development of active tubercu losis infection
Discontinuation of the study  at the request of [COMPANY_009] , aregulatory  agency  or an institutional 
review board or independent ethics committee ( IRB/IEC )
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 61 21October [ZIP_CODE].8. Bone Mineral Density Evaluations
For all subjects who are on study  drug, excluding those e nrolled in sites based in German y, dual 
energy  x-ray absorptiometry  (DXA) scans will be performed prior to or within 24 hours of 
Day 1, Weeks 24, 48, Unblinding Visit and the Early  Study  Drug Discontinuation Visit (if the 
last scan was acquired > 12 weeks from the date of the ESDD Visit) .  Scans will cover the spi[INVESTIGATOR_110077] . DXA scan results will be provided to study  
sites.
A complete description of the procedures performed for the DXA scans will be provided in a 
DXA manual.
6.9. Other Evaluations
6.9.1. Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function , which 
will includ e urine albumin, urine creatinine, urine protein, retinol binding protein and bet a-[ADDRESS_122359] 
Week 48 and the Unblinding Visit for selected evaluations of platelet function, which may  
include but not limited to soluble glycoprotein VI (sGPVI ), P-selectin, and soluble CD40 ligand
6.9.4. Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30- day 
follow -up Visit andUnscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may  beused b y the Sponsor or its research partners for HIV -1 ge notypi[INVESTIGATOR_007]/phenot ypi[INVESTIGATOR_110078] s or their development, for retesting the amount of HIV -[ADDRESS_122360] HIV-1 or clinical laboratory  testing to provide additional safety  data. No human 
genetic testing will be performed without expressed consent of study  subjects. At the conclusion 
of this study ,these samples may  be retained in storage by  [CONTACT_110100] d Sciences for a period up to 
15years.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122361] discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow -up and proc edures (see Section 6.7, Criteria for Discontinuation of Study  Treatment ). If 
this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
6.11. End of Study
The end of stud y will be the last patient’s last observation (or visit).
6.12. Post Study Care
After a subject has completed/terminated their p articipation in the study , long -term care for the
subject will remain the responsibility  of their primary  treating ph ysician.
6.13.
Virologic Failure
Virologic failure is def ined as virologic rebound or having HIV -1 RNA ≥50copi[INVESTIGATOR_014]/mL at study
drug discontinuation, or Week 48.
6.13.1. Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:
At any  post Day  1 visit , a rebound in HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL , which is subsequently  
confirmed at the following scheduled or unscheduled visit; OR
Any subject with HIV RNA 
≥ 50 copi[INVESTIGATOR_014]/mL  at study  drug discontinuation
Following the unconfirmed virologic rebound, subjects will be ask ed to return to the clinic for a 
scheduled or unscheduled blood draw ([ADDRESS_122362] that resulted 
in HIV -1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled o r unscheduled visit and the HIV -1 RNA is ≥ 200copi[INVESTIGATOR_014]/mL , the 
blood sample from the confirmation visit will be the primary  sample used for HIV -[ADDRESS_122363]’s first post -baseline resistance test, additional 
testing will be conducted on a case -by-case basis.     Any  subject may  be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resista nce is detected from the genot ype or phenotype, the subject may remain on study 
drugs and HIV -[ADDRESS_122364] should be repeated ([ADDRESS_122365] with HI V-1 RNA 
≥50 copi[INVESTIGATOR_014]/mL ). Investigators should carefully  evaluate the benefits and risks of r emaining on 
study  drug for each individual subject and doc ument this assessment in the on -site medical 
record.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 63 21October 2015Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment gui delines. Investigators who opt to discontinue 
study  drugs for an individual subject must discuss with the Medical Monitor prior to study  drug 
discontinuation.
For subjects who are off study  drug but remain on study , it will be the Investigator’s discretion to 
manage virologic rebound.
Please refer to Figure 6-1for the management of subjects who meet the criteria for virologic 
rebound.
Figure6-1. Virologic Rebound Schema
a. If virologic rebound is not confirmed, the subject will remain on their current regimen.
b. If virologic rebound is confirmed and the HIV -1 RNA is ≥
200copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase, protease and integrase) will be analyzed.
c. Based on the results of the genotyp ic and phenotyp icassays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotypi[INVESTIGATOR_110079], a new ARV regimen may be configured at the discretion of the 
Investigator.
d. If no resistance is detected, HI V
-1 RNA will be repeated (2 -3 weeks later).  Investigator reviews study drug 
continuation/discontinuation options and discuss with the Medical Monitor prior to study drug discontinuation
e. A new ARV regimen will be configured, at the Investigator’s discretio n, and the subject will remain in the study.

GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 64 21October [ZIP_CODE].13.2. Subjects with HIV-1 RNA ≥ 50copi[INVESTIGATOR_014]/mL at Study Drug Discontinuation, or 
Week 48
Subjects with HI V-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  at study  drug discontinuation or last visit will be 
considered virologic failures. Subjects with H IV-1 RNA 
≥50 copi[INVESTIGATOR_014]/mL  at Week [ADDRESS_122366]. 
Subjects with HI V-1 RNA ≥ 200 copi[INVESTIGATOR_014]/mL  at study  drug disc ontinuation, last visit or Week 48, 
will also have resistance testing conducted. 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 65 21October [ZIP_CODE]. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal p roduct, which does not necessarily  have a causal relationship with the 
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medicinal product. AEs may  also include pre -or post -treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or 
occupational exposure .Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, and transfusi on. 
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in w hich the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_10801]-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 66 21October 2015Persistent or signific ant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_110080]. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency  room or at home for allergic bronchospasm; blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical signi ficance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_122367] the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5
.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final revi ew and confirmation of accuracy  of event information 
and assessments
.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therap y using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurr ent illness, or concomitant medication).
Yes: There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 67 21October 2015It should be emphasized that ineffective treatment should not be considered as causall y related in 
the cont ext of adverse event reporting.
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other tha n the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg,venipun cture)
7.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may  not be in agreement with the grading of 
the laboratory  abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity , but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying c onditions; this may  or may  not be in agreement 
with the grading of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF:
all SAEs and adverse events related to protocol -mandated procedures.
7.3.1. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until 30-days after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122368] consents to 
participate in the stud y (i.e, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 
30-days of the 
last dose of study  IMP, regardless of causalit y, should also be reported.
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant t o the use of IMP, he/she should promptly  document and report 
the event to [COMPANY_009] DSPH .
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] D SPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not function ing, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
[COMPANY_009] DSPH contact 
[CONTACT_3031]:Email: Safety [EMAIL_202]
Fax: +1 (650) 522 -5477
As soon as it is possible to do so, any  SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto t he concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 69 21October 2015For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by  e-mail or fax only when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
7.4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, 
[COMPANY_009] may  berequired to expedite to 
worldwide re gulatory  agencies reports of SAEs , serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify  worldwide re gulatory  
agencies and the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_10855] i nvestigator’s brochure or relevant local label as applicable.
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any  study  IMP. The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the GSI Grading Scale for Severit y of Adverse Events and Laboratory Abnormalities 
(Appendix 4)
Grade [ADDRESS_122369] discontinuation, unless such a delay  is not consistent with good medical practice
Any questions regarding toxicity  management should be directed to the [COMPANY_009] Medical 
Monitor .
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the Investigator.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 70 21October [ZIP_CODE].5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade [ADDRESS_122370].
For a Grade [ADDRESS_122371] should be withheld until the toxicity  returns to 
Grade 2.When restarting investigational medicinal product following resolution of the 
adverse event, the investigational medicinal product should be restarted at full dose upon 
discussion with the [COMPANY_009] Sciences Medical Monitor.
If a laboratory  abnormality  recurs to Grade [ADDRESS_122372] may not require permanent discontinuation but 
requires discussion with the [COMPANY_009] Sciences Medical Monitor.
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade [ADDRESS_122373]. A clinically  significant Grade 4 laboratory abnormalit y that is not confirm ed by 
[CONTACT_110101].
Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product requ ires discussion with the 
[COMPANY_009] Sciences Medical Monitor.
7.5.4. Management of Possible Abacavir Hypersensitivity Reaction
Abacavir should not be used in patients known to carry the HLA -B*5701 allele due to increased 
risk of hy persensitivity  reaction, unless no other therapeutic option is available based on the 
treatment history  and resistance testing.
In a clinical stud y, 3.4 % of subjects with a negative HLA -B*5701 status receiving abacavir 
developed a h ypersensitivity  reaction. Therefore, even in the absence of HLA
-B*5701 allele, it is 
important to permanently discontinue abacavir and not rechallenge with abacavir if a 
hypersensitivity  reaction cannot be ruled out on clinical grounds, due to the potential for a severe 
or even fatal reaction.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122374] fever and/or 
rash as part of the s yndrome. Other signs and s ymptoms may  include respi[INVESTIGATOR_110081], sore throat, cough, and abnormal chest x -ray findings
(predominantl y infiltrates, which can be localized), gastrointestinal symptoms, such as nausea, 
vomiting, diarrhea, or abdominal pain, and may  lead to misdiagnosis of hypersensitivity  as 
respi[INVESTIGATOR_23715] (pneumonia, bronchitis, pharyngitis), or gastroe nteritis. Other frequentl y 
observed signs or s ymptoms of the hy persensitivity  reaction may  include lethargy  or malaise and 
musculoskeletal sy mptoms (my algia, rarely  myolysis, arthralgia). The sy mptoms related to this 
hypersensitivity  reaction worsen with c ontinued therapy  and can be life -threatening. 
These symptoms usually  resolve upon discontinuation of abacavir.
Hypersensitivity  reaction sy mptoms usually  appear within the first six weeks of initiation of 
treatment with abacavir, although these reactions may occur at any  time during therapy . Patients 
should be monitored closely , especiall y during the first two months of treatment with abacavir.
Regardless of their HLA -B*[ADDRESS_122375] be permanentl y 
discontinued if hy persensitivity  cannot be ruled out, even when other diagnoses are possible 
(respi[INVESTIGATOR_96613], flu -like illness, gastroenteritis or reactions to other medicinal products) 
{[ZIP_CODE]} .
7.5.5. On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or sy mptoms of active 
Hepatitis C virus [COMPANY_009] recommends that local medical practice is followed at the discr etion of 
the Investigator. Investigational medicinal product may  be continued without dose 
interruption. Should the Investigator decide to initiate Hepatitis C treatment the I nvestigator 
must contact [CONTACT_110102]- drug interactions are expected.
Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to 
local medical practice for laboratory  evaluations. If Hepatitis C treatment is initiated, 
Investigators should use the [COMPANY_009] pro vided retest laboratory kits to manage the active 
Hepatitis C.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy  reports regardless of an 
associated AE.  
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122376] labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be estab lished 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.
7.6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , inclu ding the post study  drug follow -up 
period, to the [COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware 
of the pregnancy . 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in [ADDRESS_122377] information is as follows:
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 73 21October 2015Email: Safety _FC@gilead. com and Fax: +1 (650) [ADDRESS_122378] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be r eported directl y to [COMPANY_009] DSPH, fax number 
+[PHONE_2520] or email [EMAIL_201].
Refer to Appendix 6for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive 
Requirements.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_122379] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications.
Special situations involving non-[COMPANY_009] concomitant medications does not need to be reported on 
the special situations report form; however, for special situati ons that result in AEs due to a 
non-
[COMPANY_009] concomitant medication, the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF completion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 74 21October [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is:
To evaluate the efficacy  of switching from a regimen of DTG and ABC/3TC or a FDC of 
ABC/DTG/3TC toa FDC of GS -9883/F/TAF versus continuing DTG and ABC/3TC as the 
FDC ABC/DTG/3TC in virologicall y suppressed HIV-[ADDRESS_122380] ed subjects as determined b y 
the proportion of subjects with virologic failure (HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48
The secondary  objectives of this study  
are:
To evaluate the safet y,and tolerability  of the two treatment groups through Week 48
To evaluate the bone safety  of the two treatment group s as determined b y the percentage 
change from baseli ne in hip and spi[INVESTIGATOR_110082] 48
8.1.2. Primary Endpoint
The primary  efficacy  endpoint is the proportion of subjects with virologic failure (HIV
-1 RNA
≥50 copi[INVESTIGATOR_014]/mL ) at Week 48 as defined b y the modified US FDA snapshot algorithm.
8.1.3. Secondary Endpoint
Secondary  endpoints include:
The proportion of subjects with H IV-1 RNA < 50copi[INVESTIGATOR_014]/mL  at Week 48 as defined b y the 
US FDA snapshot algorithm
The change from base line in CD4+ cell count at Week 48
The percent agechange from baseline in hip and spi[INVESTIGATOR_110075] 48
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. All Randomized
The randomized anal ysis set includes all subjects who are randomized into the study . This is the 
primary  anal ysis set for by -subject listings.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 75 21October [ZIP_CODE].2.1.2. Efficacy
[IP_ADDRESS].1. Full Anal ysis Set (FAS)
The primary  anal ysis set for efficacy  anal yses is defined as fullanalysis set (FAS), which will 
include all subjects who (1) are randomized into the study  and (2)have received at least 1 dose 
of study  drug .Subjects will be grouped according to the treatment to which they  were 
randomized.
[IP_ADDRESS].2. Per- Protocol (PP) Anal ysis Set
The secondary  analy sis set for efficacy  analy ses is defined as per-
protocol (PP) analysis set, 
which will incl ude all subjects who (1) are randomized into the stud y, (2)have received at least 
1dose of study  drug, and (3)have not committed any  major protocol violation, including the 
violation of key  entry  criteria. Subjects will be grouped according to the treat ment they  actuall y 
received.
Subjects meeting an y of the following criteria will be excluded from the Week 48 PP analy sis
set:
Subjects who do not have on
-treatment HIV- 1 RNA in the Week 48analysis window, except 
when missing is due to discontinuation of s
tudy drug for lack of efficacy .
Subjects who meet the exclusion criterion for receiving ongoing therap y with any  of the 
medications listed in the table in protocol Section 4.3including drugs not to be used with 
GS-9883, FTC, TAF, ABC, 3TC, and DTG.
Nonadherence to stud y drug: subjects with adherence rate for active study  drug up to the 
Week 48 Visit below the 2.5th percentile
[IP_ADDRESS]. Safety
The primary  anal ysis set for safety anal yses is defined a s safety  
analysis set, which will include 
all subjects who (1) are randomized into the study  and (2) have received at least 1 dose of stud y 
drug. All the data collected up to 30 day s after subjects permanently  discontinue their study  drug 
will be included in the safety  summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they  actually  received.
[IP_ADDRESS]. Pharmacokinetics
[IP_ADDRESS].1. Pharmacokinetic (PK) Substudy  Anal ysis Set
The primary  anal ysis set for intensive PK anal yses is defined as the PK substudy  anal ysis set, 
which wi ll include all subjects who (1) arerandomized into the study , (2) enrolled into the PK 
Substudy , (3) have received at leas t 1dose of study  drug, and (4) have at least 1 nonmissing 
intensive PK concentration data for the anal yte under evaluation reported by  [CONTACT_10858].
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 76 21October [ZIP_CODE].[IP_ADDRESS]. Pharmacokinetic (PK) Analy sis Set
The primary  anal ysis set for general PK analy ses is defined as the PK analysis set, which will 
include all subjects who (1)are randomized into the study , (2) have recei ved at least 1 dose of 
study  drug, and (3) have at least 1 nonmissing PK concentration data for the anal yte under 
evaluation reported b y the PK lab.
[IP_ADDRESS]. DXA
[IP_ADDRESS].1. Hip D XA Anal ysis Set
The primary  anal ysis set for hip BMD anal yses is defined as the Hip DXA analysis set, which
willinclude all subjects who (1) are randomized into the stud y, (2) have received at least 1 dose 
of study  drug, and (3) have nonmissing baseline hip BMD value. Subjects will be grouped 
according to the treatment they  actually  received.
[IP_ADDRESS].2. Spi[INVESTIGATOR_050] D XA Anal ysis Set
The primary  anal ysis set for spi[INVESTIGATOR_110083], 
which willinclude all subjects who (1)are randomized into the stud y, (2) have received at least 
1dose of study  drug, and (3) have nonmis sing baseline spi[INVESTIGATOR_110084]. Subjects will be 
grouped according to the treatment they  actually  received.
8.3. Data Handling Conventions
HIV-1 RNA results of ‘No HIV -1 RNA detected’ and “<20 cp/mL  HIV
-1 RNA Detected” will 
be imputed as 19 copi[INVESTIGATOR_014]/mL  for anal ysis purpose .
Natural logarith mic transformation of plasma concentrations and PK parameters will be applied 
for PK anal ysis.
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit plus 
or minus one significant digit, respectivel y (eg, if the result of a continuous laboratory test is 
<20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretat ion of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre -treatment laboratory  result would be 
treated as normal (ie, no toxicity  grade) for the laboratory  abnormality  summary .
All available data for subjects that do not complete the study  will be included in data listings.
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline characteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, mi nimum, and maximum for 
continuous variables and frequency  and percentages for categorical variables.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122381] ion, and enrollment distribution will be summarized .
For categorical demographic and baseline characteristics, the Cochran –Mantel –
Haenszel (CMH)
test will be used to compare treatment group s. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment group s.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  efficacy  endpoint is the proportion of subjects with virologic failure ( HIV-1 RNA
≥50 copi[INVESTIGATOR_014]/mL ) at Week 4
8 as defined b y the modified US FDA snapshot algorithm. The 
primary  anal ysis of the efficacy  will be based on the FAS.
[IP_ADDRESS]. M odified 
US FDA Snapshot Algorithm
The US FDA snapshot algorithm has been modified to classify  subjects who discontinue study  
drug due to adverse event or death and have thelast available on- treatment HIV -1 RNA value 
≥ 50 copi[INVESTIGATOR_014]/mL  as a Virologic Failure. In the original US FDA snapshot alogrithim, t hese 
subjects would be classified as having No Virologic Data in the Week 48 Analy sis Window.
The modified US FDA snapshot algo rithm appears below.
The anal ysis window at Week 48 is defined as from Study  Day 294 to Study  Day 377, inclusive . 
All HIV -1 RNA data collected on -treatment (ie, including data collected up to [ADDRESS_122382] 
dose date of study  drug ) will be used in the snapshot algorithm. Virologic outcome will be 
defin ed as the following categories:
Virologic Success: this includes subjects who have the last available on
-treatment HIV-1 
RNA < 50 copi[INVESTIGATOR_014]/mL in the Week 48 anal ysis window 
Virologic Failure : this include subjects
a)Who have the last available on- treatment HI V- 1RNA ≥ 50 copi[INVESTIGATOR_014]/mL in the Week 48 
analysis window, or
b)Who do not have on- treatment HIV -1 RNA data in the Week 48 anal ysis window and
1)Who discontinue study  drug prior to or in the Week 48 anal ysis win dow due to lack 
of efficacy , or
2)Who discontinue study  drug prior to or in the Week [ADDRESS_122383] availa ble on- treatment HIV -1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 78 21October 2015No VirologicData in the Week 48 Analysis Window :this includes subjects who do not 
have on -treatment HIV -1 RNA data in the Week 48 anal ysis window because of the 
following:
a)Discontinuation of study  drug prior to or in the Week [ADDRESS_122384] available on-treatment HIV-1 RNA 
< 50 copi[INVESTIGATOR_014]/mL , or
b)Missing data duri ng the window but on study  drug
[IP_ADDRESS]. Analy sis of Primary  Efficacy  Endpoint
The null hy pothesis is that the proportion of subjects with virologic failure (HIV -1 RNA 
≥ 50 copi[INVESTIGATOR_014]/mL ) at Week 48 in the GS -9883/F/TAF group is at least 4% higher than the 
virologic failure rate in the ABC/DTG/3TC group; the alternative h ypothesis is that the virolgoic 
failure rate in the GS -9883/F/TAF group is less than 4% higher tha n that in the ABC/DTG/3TC 
group.
Non-inferiorit y will be assessed using the conventional conf idence interval (CI) approach. The 
point estimate of treatment difference ( GS-9883/F/TAF –ABC/DTG/3TC ) and the associated 
2-sided 95% CI will be constructed based on the exact method.
It will be concluded that GS-
9883/ F/TAF is non -inferior to ABC/3TC /DTG if the upper bound of 
the 
2-sided 95% CI of the difference between treatment group s 
(GS-9883/ F/TAF -ABC/3TC /DTG) in the virologic failure rate is less than 4% .
If non -inferiority  of GS-9883/F/TAF to ABC/DTG/3TC is established, the upper bound of the 
95% CI  will be compared to 0; if the upper bound of the 95% CI is lessthan 0, superiority  of 
GS-9883/F/TAF over ABC/DTG/3TC will be established.
8.5.2. Secondary Analyses
The proportion of subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/mL  at Week 48 as defined b y the US 
FDA snapshot algorithm will also be evaluated. The 95% CIs will be constructed in the same 
manner as for the primary  efficacy  endpoint. However, non- inferiorit y will b e assessed using a 
margin of 10%. It will be concluded that GS -9883/F/TAF is non -inferior to ABC/DTG/3TC if 
the lower bound of the 2 -sided 95% CI  of the difference between treatment groups
(GS-9883/F/TAF – ABC/DTG/3TC) in the response rate is greater than
-10%.
The changes from baseline in CD4+ cell count at Weeks 48 will be summarized by  [CONTACT_110103]. The differences in changes from baseline in CD4+ cell count between 
the 2 treatment groups and the associated 95% CIs will be cons tructed using ANOVA models, 
including treatment (GS -9883/F/TAF vs. ABC/DTG/3TC) as a fixed effect in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) method and analy zed similarly .
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122385]’s extent of exposure to study  drug will be generated from the study  drug
administration page in eCRF . Exposure data will be summarized by  [CONTACT_3148].
Duration of exposure to study  drug will be expressed as the number of weeks between the first 
and last dose of the stud y drug , inclusive, regardless of temporary  interruptions in study  drug
administration and summarized by [CONTACT_3148].
Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laborator y adverse events will be coded using the Medical Dictionary for 
Regulatory  Activities (MedDRA). System Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T),Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event with onset date on or after the stud y drug start 
date and no later than 30 day s after the study  drug stop date; or an y adverse event leading to 
study  drug discontinuation.
Summaries (number and percentage of subjects) of treatment -
emergent adverse events (b y SOC, 
HLT[if applicable] , and PT) will be provided by  [CONTACT_3148]. Additional summaries will inclu de 
summaries for adverse events by  [CONTACT_479], Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic I llnesses in HIV are indicative of an AIDS -Defining Diagnoses. The 
[COMPANY_009] medical personnel will review the possible Stage 3 events and approve the events that 
meet the definition. Those events that do meet the Stage 3 Opportunistic I llness definition of an 
AIDS-Defining Diagnosis will be listed.
A listing of Stage 3 Opportunistic I llnesses in HIV can be found in Appendix 5.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 80 21October [ZIP_CODE].6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl y observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities attached in Appendix 4.
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
1toxicity  grade from baseline at an y time post baseline up to and including the date of last dose 
of study  drug plus 30 days, will be summarized by [CONTACT_3148]. If baseline data are missing, then 
any graded abnormalit y (ie, at least a Grade 1) will be considered treatment emergent. The 
maximum postbaseline toxicity  grade will be summarized by  [CONTACT_10862].
Laboratory  abnormalities that occur before the first dose of 
study  drug or after the last dose of 
study  drug plus 30 day s will be included in a data listing.
8.6.4. Bone Safety Evaluations
The percentage changes from bas eline in hip/spi[INVESTIGATOR_110085] 48 will be summarized by  
[CONTACT_53846]. The differences in percentage changes from baseline in 
hip/spi[INVESTIGATOR_110086] 2treatment groups and the associated 95% confidence intervals will be 
constructed using ANOVA models, including t reatment as a fixed effect in the model.
In addition, missing values for BMD will be imputed using LOCF method and anal yzed 
similarly .
8.6.5. Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate .
8.7. Pharmacokinetic Analysis
For the intensive PK substudy , plasma concentrations of GS-9883 may be summarized by  
[CONTACT_10863]. Pharmacokinetic parameters (C max, Tmax, Ctau, 
AUC tau,and T ½, as appropriate) may be listed and summarized using descriptive statistics (eg, 
sample size, arithmetic mean, geometric mean, coefficient of variation %, SD, median, Q1, Q3, 
minimum, and maximum). Plasma concentrations over time will be plotted in semi -logarithmic 
and linear formats as mean ± standard devia tion, and median (Q1, Q3).
For the general PK anal yses, t he pharmacokinetics of GS
-9883 may  be evaluated using 
descriptive statistics or population approaches.
TAF and FTC concentrations may  be anal yzed and PK parame ters summarized as applicable.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122386] .
8.9. Patient Reported Outcomes (PRO)
The PRO measures based on questionnaires (eg, SF- 36 and HIV Sy mptoms Distress Module ) 
will be summarized by [CONTACT_110104].
8.10. Sample Size
A total of approximately  520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2treatment
group s (260subjects per treatment group ), achieves at least 90% power to detect a 
non-inferiorit y margin of 4%
in Week 48 virologic failure rate (HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL) 
difference between the [ADDRESS_122387] a virologic failure rate of 2%(based on the historical 
[COMPANY_009] ECF/TAF and STB studies) , that the non-inferiorit y margin is 4%, and that the 
significance level of the test is at a one- sided 0.025 level.
8.11. DataMonitoring Committee
An external Independent Data Monitoring Committee (IDMC) will re view the progress, efficacy , 
and safet y data of this study while the stud y is ongoing. The committee will convene after the 
first [ADDRESS_122388] of 
the participants.
For each IDMC anal ysis performed prior to the analy sis of the primary  efficacy  endpoint, an 
alpha penalt y of 0.[ZIP_CODE] will be applied forthe primary  anal ysis of the primary  endpoint .
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 82 21October [ZIP_CODE]. RESPONSIBILITI ES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject . These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” [ADDRESS_122389] be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportabl e interests during the stud y and 
for [ADDRESS_122390] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, o r descriptions of the study  used to obtain 
informed consent) to an IRB/IEC . The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation , the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazar ds of the study  and before undertaking an y stud y
-related procedures. The 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122391] current IRB-or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_10865]. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laborat ory spec imens must 
be labeled in such a way as to protect subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE :The investigator must keep a 
screening log showing codes, names, an d addresses for all subjects screened and for all subjects 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator b
rochure, this protocol, eCRF , the IMP, and any  other study  information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except e mploy ees or agents directl y 
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the study  site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study  data to be subseque ntly verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion a nd exclusion criteria);
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 84 21October 2015Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures w ere performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discontinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_122392] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until th ere are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_122393] been received.  Subsequent to data entry , a study  monitor will perform source 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 85 21October 2015data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or any  interim time poi nts 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  [CONTACT_110105], 
who routinely  review the da ta for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entry, and providing the reason 
for the update (e.g. data entry  error). At the conclusion of the trial, [COMPANY_009] will provide the site 
with a read -only archive copy  of the data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.[ADDRESS_122394] Accountability and Return
[COMPANY_009] recommends that used and unused IMP supplies be returned to the shippi[INVESTIGATOR_10803]. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal 
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard o
perating procedure (SOP ) for drug destruction as determined b y 
[COMPANY_009] QA , the site may  destroy  used (empt yor partially  empty ) and unused IMPsupplies in 
accordance with th atsite’s approved SOP. A cop y of the site’s approved 
SOP will be obtained 
for central files.
If IMP is des troyed on site, the investigator must maintain accurate records for all IMP
destroy ed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copie sof the 
IMP accountability  records must be filed at the site. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source doc uments and other records for this trial to 
[COMPANY_009]
’s appointed stud y monitors , to IRBs or IECs, or to regulatory  authority  or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122395] subm it all protocol modifications to the IRB or IEC 
in accordance with local requirements and receive documented IRB or IEC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provi ded to the regulatory agency (ies). [COMPANY_009] 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investiga tors in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the results of the study in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least [ADDRESS_122396] 30 day s before submission of t he 
publication or presentation.
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transf er of value.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122397] access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsible for routine review of the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y sub ject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspecti ons
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the [COMPANY_009] medical monitor imme diately . The investigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator r eserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 88 21October 201510. REFERENCES
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
5125 Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. 
Changing patterns of mortality  across Europe in patients infected with HIV -1. 
Lancet 1998;352 (9142):1725-30.
8284 Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term 
effectiveness of potent antiretroviral therapy  in preventing AIDS and death: a 
prospective cohort study . Lancet 2005;366 (9483):378-84.
[ZIP_CODE] Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. 
Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS 
among children aged 18 months to <13 y ears--[LOCATION_002], 2008. MMWR 
Recomm Rep 2008;57 (RR- 10):1-12.
[ZIP_CODE] Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self -reported 
adherence supports patient preference for the single tablet regimen (STR) in the 
current cART era. Patient preference and adherence 2012;6:427 -33.
[ZIP_CODE] Ezzati M, L opez AD. Estimates of global mortality  attributable to smoking in 
2000. L ancet 2003;362 (9387):847-52.
[ZIP_CODE] Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. 
Declining Morbidity  and Mortality  Among Patients With Advanced Human 
Immunodeficiency  Virus I nfection. N Eng J Med 1998;338 (13):853-60.
[ZIP_CODE] Aldir I , Horta A, Serrado M. Single -tablet regimens in HI V: does it reall y make a 
difference? Curr Med Res Opin 2013;30 (1):89 -97.
[ZIP_CODE] Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-301.
[ZIP_CODE] Department for Heal th and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV -1-Infected Adults and Adolescents. Developed by  
[CONTACT_10868] –A 
Working Group of the Office of AIDS Research Adv isory  Council (OARAC). 
Downloaded from http://aidsinfo.nih.gov/guidelines on 5/11/2015. L ast Updated 
[ADDRESS_122398] Sheet: 2014 Global Statistics. 
Available at: 
http://www.unaids.org/sites/default/files/ media_asset/20150714_FS_MDG6_Rep
ort_en.pdf .  2014.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 89 21October 201511. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table (Blinded Phase)
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Require ments
GS-9883/F/TAF 
Protocol GS-US-380- I [ADDRESS_122399] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized , Double-Blind Study to Evaluate the Safety and Efficacy of 
Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination 
(FDC) of ABC/DTG/3TC to a FDC ofGS-9883 /F/TAF in HJV-[ADDRESS_122400] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervisio n copi[INVESTIGATOR_10805], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) Signature 
[CONTACT_10885] 90 21 October 20 I 5 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 91 21October 2015Appendix 2. Study Procedures Table (Blinded Phase)
Study Procedures ScreeningaDay 1bEnd of Weeke, pPost-Week 48e, q
Unblinding 
Visit30-Day 
Follow-upoEarly 
Study 
Drugs 
DCc4 8 12 24 36 48 Every 12 Weeks
Informed Consent X
Medical History X
Concomitant Medications X X X X X X X X X X X X
Adverse Events X X X X X X X X X X XfXf
Complete /Symptom -Directed 
Physical ExamX X XdXdXdX XdX XdX Xd,fXf
12-Lead ECG (performed 
supi[INVESTIGATOR_050])X X X X X X
Questionnaires X X X X
DXA scan (spi[INVESTIGATOR_050] & hip)gX X X X X
Height X
Vital signs (blood pressure, 
pulse, respi[INVESTIGATOR_1487], and 
temperature), includin g 
WeightX X X X X X X X X X X X
Urinalysis X X X X X X X X X X XfXf
Urine Pregnancy TesthX X X X X X X X X X X
Serum Pregnancy Test X
Chemistry ProfileiX X X X X X X X X X XfXf
Metabolic AssessmentsjX X X X XrX
GS-9883/F/T AF 
Protocol GS-US-380-1844 
[COMPANY_009] Sciences, Inc. 
Study Procedures 
Estimated Glomemlar 
Filtration Rate 
Hematology Profilek 
Plasma HIV -1 RNA 
CD4+ Cell Connt 
Evaluations of inflanunation 
and immnne activation, 
platelet fimction and renal 
tubular fimction 
Plasma & Urine Storage 
Sample 
Whole Blood sample for 
potential HIV DNA 
genotypi[INVESTIGATOR_110087] -1 Genotype/Phenotype e 
Single PK Sample1 
Trough PK Samplesm 
Optional [COMPANY_003] I' I ~ 
CONFIDENTIAL Screening• Day lb 4 8 
X X X X 
X X X X 
X X X X 
X X X X 
X 
X X X 
X 
X 
X 
X 
X End ofWeek• ,p Post-Week 48•,q 
12 24 36 48 Every 12 Weeks 
X X X X X 
X X X X X 
X X X X X 
X X X X X 
X X xr 
X X X X X 
X X 
X 
Page 92 Unblindin g 
Visit 
X 
X 
X 
X 
X 
X 30-Day 
Follow-up0 
xr 
xr 
X 
X Final 
Original 
Early 
Study 
Drugs 
nc< 
X 
xr 
X X 
X 
xe 
21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122401] discontinues study drug.
d S ymptom -directed physical examination as needed.
e HIV-1 genotype and phenotype testing for subjects with virologic failure . Following virologic rebound, subjects will be a sked to return to the clinic (2-3 weeks later) prior to 
the next scheduled visit or at the next schedul ed study visit, for a HIV -1 RNA and HIV -1 genotype and phenotype (reverse transcriptase , protease , and integrase genotype and 
phenotype ) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section 6.13.1 and 6.13.2 ).
f Any adverse event or test showing abnormal results that is believed to have a possible or probable causal relationship with t he study drug will be repeated weekly (or as often 
as deemed prudent by [CONTACT_737]) until the abnormality is resolved, return s to Day 1 , or is otherwise explained.
g DXA scans to be performed in all eligible subjects on study drug, except for those in [LOCATION_013], prior to or within 24 hours of th
e Day 1 Visit, Weeks 24, 48 (±10 days), and at
Unblinding Visit (±10 days )and the ESDD visit (if the last scan was acquired > 12 weeks from the date of the ESDD Visit) .
h Females of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test.
i Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bili rubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid and amylase (reflex lipase testing is performed in subjects with total amy lase 
1.5ULN) At Day 1, Weeks 12, 24, 48 and Unblinding Visit, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the ch emistry 
profile. Additionally: TSH will be analyzed at Screening, Day 1, Weeks [ADDRESS_122402] Week 48, U nblinding Visit and Early Study Drugs 
Discontinuation visit.
j Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total choleste rol, H DL, direct LDL, tri glycerides). If the subject has 
not fasted prior to the visit, the visit may proceed, but the subject must return within [ADDRESS_122403] dose.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 94 21October 2015n A PK substudy will be performed in a subset of subjects (n=30) at selected study sites.  The pharmacokinetic substudy visit mus t occur at the Week4 orWeek8visits. The 
substudy will include intensive PK profiling in plasma
o Only required for those subjects not enrolling in the open -label rollover extension or those subjects who permanently discontinue study drugs and do not continue in the study 
through at least one subsequent visit after the Early Study Drugs Discontinuation Visit. For the purpose of scheduling a 30 -Day Follow -Up Visit, a 6days window may be 
used.
p Study visits are to be completed within ± 2 days of the protocol-specified visit date based on the Day 1 visit through Week 12 a nd completed within ± 6days thro ugh to 
Week 36, unless otherwise specified. The visit window at Weeks 48 will be ± [ADDRESS_122404] been unblinded. Visit window of 
6days for study visits post Week 48 .  After Week 48 Visit, subjects in the [LOCATION_008] ([LOCATION_006]) and Sweden (S WE) will stop taki ng study drug and complete a 30 day 
follow up visit .
r To be performed every 24 weeks after Week 48until Unblinding Visit.
s Open label study drug, GS-9883/F/TAF FDC will be dispensed to subjects participating in the Open-
Label Rollover extension.
t Randomization may be performed up to [ADDRESS_122405] eligibility has been 
confirmed.
GS-9883/Fff AF 
Protocol GS-US-380-1844 Final 
[COMPANY_009] Sciences, Inc. Original 
Appendix 3. Management of Clinical and Laboratory Adverse Events 
Grade 1 
L------G-ra_d_e_2----~~ ~~ ______ G_rn_d_e_3----~~ ~~ _________ G_rn_d_e_4--------~ 
! ! 
May continue dosing Repeat lab to 
at the discretion of confirm toxicity 
the investigator grade 
If confmned and possibly and/or probably related to investigational 
medicinal products: 
I. Withhold investigational medicinal products until ~ Grade 2 
2. Restart all investigational medicinal products at full dose 
1 
If Grade 3 or 4 recurrence that is confirmed and possibly or probably 
related to investigational medicinal products, discontinu e all 
investigat ional medicinal products dosing permanently 1 Repeat lab to 
confirm toxicity 
grade 
1 If confirmed and 
possibly or probably 
If c onfirmed and unrelated to 
stigational medicinal products, 
tng may continue at the discretion 
the investigator ---+ related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to inve 
dos 
of 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL Page 95 21 October 2015 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 96 21October 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months #1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 97 21October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.[ADDRESS_122406] >1.[ADDRESS_122407] >2.[ADDRESS_122408] >3.[ADDRESS_122409]
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 98 21October 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Activated Partial
Thromboplastin Time (APTT)1.00 to 1.66ULN 1.66 to 2.33ULN 2.33 to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0%
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the [COMPANY_009] convention of grading 
any resu lt within the LLN and ULN a 0.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 99 21October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN   to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN   to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to   <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant<1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                 
2.5 to <3.0 mmolL2.0 to2.5mEq/L                  
2.0 t o <2.5 mmolL2.0 mEq/L                          
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant<1 Year >ULN to 6.0 m Eq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L              
6.5 to 7.0 mmol /L7.0 mEq/L                   
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to55mg/d L
2.20 to3.03 mmol/L30 to40mg/d L
1.64 to2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 100 21October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate* )
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmo l/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1 mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate* )
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 101 21October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmo l/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to2.0 mg/dL
0.47 to0.63 mmol/L1.0 to1.5 mg/dL
0.31 to0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmo l/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmo l/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 102 21October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year    
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50to 2.00 mg/dL
133to 177μmol/L2.00to 3.00 mg/dL
177to 26 5 μmol/L3.00 to 6. 00 mg/dL 
265to 530 μmol/L6.00 mg/dL
53 0 μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 103 21October 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calc ium should be cor rected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’ snormal range for creatinine may result for Male subjects >[ADDRESS_122410] a 0.
GS-9883/F/TAF
Protocol GS -US-380-[ADDRESS_122411] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 105 21October 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999mg/24 h >999 to1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499 to799mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Note s:
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assig ned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 106 21October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac A rrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac- ischemia/I nfarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (wit h repeat 
testing at same visit)140–159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial E ffusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusi on requiring no 
interventionEffusion with non-life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 107 21October 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric [ADDRESS_122412] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/E mbolism NA Deep vein thrombosis AND 
No intervention indicated ( eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated ( eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event ( eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 108 21October 2015RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_696] f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 109 21October 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_110106] – Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 110 21October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetit e without 
decreased oral intakeLoss of appetite associated with 
decreased oral intake w ithout 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [ eg, tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention
indicated ( eg, diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstr uction)
Diarrhea 
Adult and Pediatric 
1 YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 111 21October 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/S tomatitis 
(clinical exam)
See also Pr octitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
conseque nces ( eg, aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage )
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfor t AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_110088]-threatening consequences 
(eg, hypotensive shock)
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 112 21October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in M ood ( eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causing in ability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others ( eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dem entia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional ac tivities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive a nd 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & funct ional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual socia l & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 113 21October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 114 21October 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive ( eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg, refractory 
epi[INVESTIGATOR_002])
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_10819]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality ( eg, 
severity or focality) Seizures of any kind that are 
prolong ed, repetitive ( eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg, refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without second ary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_122413] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 115 21October 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform ba sic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 116 21October 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralize d urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/ malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain- Indicate Body  Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [ eg, 
tube feeding or total parenteral 
nutrition]
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 117 21October 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site P ain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basi c self -care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (invo lving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythema OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment ( eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment ( eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 118 21October 2015ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( eg, back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_110107][INVESTIGATOR_10820]-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, myxedema coma)
Lipoatrophy ( eg, fat loss 
from the face, extremities , 
buttocks)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10877]-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 119 21October 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_110108] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary T ract 
obstruction ( eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic anti μbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic anti μbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences ( eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a hobby, etc.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 120 21October 2015Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC 
Guidelines)
1.Candidiasis of bronchi, trachea
,or lungs
2.Candidiasis of esophagus
3.Cervical cancer, invas ive
4.Coccidioidomy cosis, disseminated or extrapulmonary
5.Cryptococcosis, extrapulmonary
6.Cryptosporidiosis, chronic intestinal ( 1month duration)
7.Cytomegalovirus disease (other than liver, spleen or nodes)
8.Cytomegalovirus retinitis (with loss of vision)
9.Encephalopath y, HIV-related
10. Herpes simplex: chronic ulcer(s) ( 1month duration); or bronchitis, pneumonitis or 
esophagitis
11.Histoplasmosis, disseminated or extrapulmonary
12.Isosporiasis, chronic intestinal ( 1month duration)
13.Kaposi’s sarcoma
14.Lym phoma, Burkit t’s (or equivalent term)
15.Lym phoma, immunoblastic (or equivalent term)
16.Lym phoma, primary , of brain
17.Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
18.Mycobacterium tuberculosis , of any  site,  pulmonary , disseminated or extrapulmonary
19.Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20.Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii ) pneumonia
21.Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23.Salmonella septicemia, recurrent
24.Toxoplasmosis of brain
25.Wasting sy ndrome attributed to HIV infection
CDC Stage -3-Defining Opportunistic I llnesses in HIV Infection - 2014 {[ZIP_CODE] }
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 121 21October 2015Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documented ovarian failure.
Women are considered to be in a postmenopausa l state when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 month s without an alternative cause. In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimula ting hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpi[INVESTIGATOR_10822] a female subject of any age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered to be fertile after the initiation 
of pubert y unless permanently  sterile b y bilateral orchidectom y or medical documentation.
2)Contraception Requirements for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS -9883/F/TAF in pregnant women is limited or not available. There is no 
suspi[INVESTIGATOR_10823]. Relevant non-
clinical reproductive studies for human pregnancy  do not indicate a strong suspi[INVESTIGATOR_10824] y/fetotoxicity .Data from clinical pharmacokinetic interaction studies of GS-9883 
and F/TAF have demonstrated that there is no reduction in the cli nical efficacy  of hormonal 
contraception or that the effect on hormonal c ontraception is insignificant. Please refer to the 
latest version of the GS-9883/F/TAF investigator’s brochure and the current Prescribing 
Information and local product labeling for A BC/DTG/3TC for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  They  must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Day  [ADDRESS_122414] 
will be performed at the end of relevant s ystemic exposure. In the event of a delay ed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy . This is true even for women of childbearing potential with infrequent or irregular 
periods . Female subjects must a gree to one of the fo llowing from Screening until 30 days 
following the end of relevant sy stemic exposure.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 122 21October 2015Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below.
Intrauterine device (IUD) with a failure rate of <1% per year
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of <1% per y ear
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 mont hs after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Consistent and correct use of one hormonal method and one barrier method
Barrier m ethods
■ Diaphragm with spermicide
■Cervical cap with spermicide
■Male condom (with or without spermicide)
Hormonal methods
■Oral contraceptives (either combined or progesterone only )
■Injectable progesterone
■Implants of levonorgestrel
■ Transdermal contraceptive patch
■Contraceptive vaginal ring
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure.
GS-9883/F/TAF
Protocol GS -US-380-1844 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page 123 21October [ZIP_CODE]) Contraception Requirements for Male Subjects
It is theoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefore, male subjects with female 
partners of childbearing potential must use condom s during treatment and until [ADDRESS_122415] also refrain from sperm donation during treatment and until at leas t 90days 
after the end of relevant systemic exposure.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant during the stud y must report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.3.